Stress-associated and virulence genes	Protein encoded/function

Oxidative stress

oxyR	DNA-binding transcriptional regulator OxyR

sodA	Manganese-containing superoxide dismutase

soxR	Redox-sensitive transcriptional activator of oxidative stress regulon

General stress

uspA	Universal stress global response regulator

rpoS	Regulator of the general stress response (σS)

Starvation

phoA	Alkaline phosphatase

dps	DNA-binding protein from starved cells

Cold shock

cspA	Cold shock protein A

cspC	Cold shock protein C

cspE	Cold shock protein E

UV

mutS	DNA mismatch repair protein—Mutator S

Acid resistance

gadA	Glutamate decarboxylase A

gadB	Glutamate decarboxylase B

gadW	DNA-binding transcriptional activator GadW

Intimin

eae	Intimin (adherence protein)

Toxin

stx1A	Shiga-like toxin 1 A subunit

stx2A	Shiga-like toxin 2 A subunit

Motility

fliC	Flagellin

Stress-associated and virulence genes

Oxidative stress

oxyR

sodA

soxR

General stress

uspA

rpoS

Starvation

phoA

dps

Cold shock

cspA

cspC

cspE

UV

mutS

Acid resistance

gadA

gadB

gadW

Intimin

eae

Toxin

stx1A

stx2A

Motility

fliC

Protein encoded/function

Oxidative stress

DNA-binding transcriptional regulator OxyR

Manganese-containing superoxide dismutase

Redox-sensitive transcriptional activator of oxidative stress regulon

General stress

Universal stress global response regulator

Regulator of the general stress response (σS)

Starvation

Alkaline phosphatase

DNA-binding protein from starved cells

Cold shock

Cold shock protein A

Cold shock protein C

Cold shock protein E

UV

DNA mismatch repair protein—Mutator S

Acid resistance

Glutamate decarboxylase A

Glutamate decarboxylase B

DNA-binding transcriptional activator GadW

Intimin

Intimin (adherence protein)

Toxin

Shiga-like toxin 1 A subunit

Shiga-like toxin 2 A subunit

Motility

Flagellin


Gene	Sequence 5’to 3

MAPK	Forward	CAGTGGGATGGAATTGAAAG

	Reverse	AGCAGAAGGAATGAGTGTGC

NOS1	Forward	GACTGTTGAGATGGAAGAAC

	Reverse	ATCTTCCTGTCTCCGAGGCG

NOS3	Forward	GTGATGGCGAAGCGAGTGAAG

	Reverse	CCGAGCCCGAACACACAGAAC

PIK3CA	Forward	CTCCACGACCATCATCAGG

	Reverse	GATTACGAAGGTATTGGTT


	low fCP	high fCP	P values

	lo	high	l	hig	fC	fCHO	fC


Species	Erroneous sequences	Corrected sequences	Apparent rate of correction (%)

H. sapiens	941	331	35.2

M. musculus	455	106	23.3

R. norvegicus	704	178	25.3

M. domestica	434	93	21.4

G. gallus	458	118	25.8

X. tropicalis	547	176	32.2

D. rerio	1376	180	13.1

F. rubripes	507	97	19.1

B. floridae	1753	46	2.6

C. intestinalis	391	28	7.2

C. elegans	215	49	22.8

D. melanogaster	337	60	17.8

Species	Erroneous sequences	Corrected sequences	Apparent rate of correction (%)

D. melanogaster	337	60	17.8


characteristics	C/G/BMSCs-dECM scaffolds	C/G scaffolds

Pore diameter (μm)	289.17 ± 80.28	227.17 ± 44.37

Porosity (%)	89.25 ± 3.75	88.48 ± 2.28

Water uptake ratio	13.81 ± 1.00	11.07 ± 0.87

Compressive modulus (MPa)	0.82 ± 0.07	1.10 ± 0.11

characteristics	C/G/BMSCs-dECM scaffolds

Pore diameter (μm)	289.17 ± 80.28

Porosity (%)	89.25 ± 3.75

Water uptake ratio	13.81 ± 1.00

Compressive modulus (MPa)	0.82 ± 0.07


Defense related transcripts Leaf	Stress related transcripts Leaf

EST/mRNA	Fold	Description	EST/mRNA	Fold	Description

EH615198	6.4	Nicotiana tabacum nictaba mRNA (NT1)	TA14956_4097	3.8	Tamarix Putative stress-responsive protein

FG636567	3.8	Nicotiana tabacum mRNA for P-rich protein NtEIG-C29	FG156808	3.6	Nicotiana tabacum 1-D-deoxyxylulose 5-phosphate synthase mRNA (DXS1)

EB433973	2.8	Parsley PcPR1-3 mRNA for pathogenesis-related protein type B	CV016057	2.9	Arabidopsis thaliana cold-regulated 413-plasma membrane 2 mRNA COR413-PM2

S44869	2.4	Nicotiana tabacum Endochitinase A precursor	EB441160	2.9	Solanum lycopersicum dxs2 gene for 1-deoxy-D-xylulose 5-phosphate synthase

X12739	2.1	Nicotiana tabacum Pathogenesis-related protein R major form precursor	EB435759	2.8	Ipomoea nil In04 mRNA for caffeoyl-CoA O-methyltransferase

TA14009_4097	0.5	Nicotiana tabacum Chitinase 134	TA12600_4097	2.8	Solanum tuberosum Low temperature and salt responsive protein

EB425556	0.5	Arabidopsis thaliana beta-1,3-glucanase-related mRNA	EB451519	2.8	Solanum lycopersicum geranylgeranyl pyrophosphate synthase 1 (GGPS1)

EH624302	0.5	Arabidopsis thaliana callose synthase 1 mRNA CALS1	EB445705	2.7	Vitis vinifera RD22-like protein mRNA

Defense related transcripts Flower	DV161729	2.1	Arabidopsis thaliana snf1-related protein kinase 2.2, SNRK2.2

FG167555	3.8	Nicotiana tabacum Avr9/Cf-9 rapidly elicited protein 111B (ACRE111B) AP2-DOMAIN	FG633784	2.0	Solanum lycopersicum anthocyanin acyltransferase mRNA, Jasmonic acid inducible

AB041516	3.5	Nicotiana tabacum P-rich protein EIG-I30	EB680165	0.3	Arabidopsis thaliana SIP3 (SOS3-INTERACTING PROTEIN 3)

TA14524_4097	3.0	Nicotiana tabacum Avr9/Cf-9 rapidly elicited protein 65 (ACRE65) mRNA,	EB433693	0.4	Arabidopsis thaliana AFP1 (ABI FIVE BINDING PROTEIN)

FG640154	2.6	Nicotiana tabacum mRNA for basic pathogenesis-related protein Thaumatin	TA14058_4097	0.4	Ipomoea nil CHS-D mRNA for chalcone synthase

FG635113	2.5	Nicotiana tabacum Avr9/Cf-9 rapidly elicited protein 20 (ACRE20) mRNA; EF-hand calcium binding protein	EB439278	0.4	Nicotiana tabacum NtERD10B mRNA for dehydrin

TA13004_4097	2.2	Nicotiana tabacum mRNA for hin1 gene: Harpin inducing protein	EB437158	0.5	Ricinus communis leuco-anthocyanidin dioxygenase mRNA

TA15227_4097	2.1	Nicotiana tabacum Avr9/Cf-9 rapidly elicited protein 76; NDR1/HIN1	DW003496	0.5	Ricinus communis Salt-tolerance protein

AB127582	2.1	Nicotiana tabacum Harpin inducing protein 1-like 18 DOMAIN: LEA_2	EB438355	0.5	Arabidopsis thaliana ATHK1 (histidine kinase 1/ osmosensor)

			EB438355	0.5	Catharanthus roseus cold inducible histidine kinase 1 (iK1) mRNA

Defense related transcripts Leaf	Stress related transcripts Leaf

EST/mRNA	Fold	Description	EST/mRNA	Fold

EH615198	6.4	Nicotiana tabacum nictaba mRNA (NT1)	TA14956_4097	3.8

FG636567	3.8	Nicotiana tabacum mRNA for P-rich protein NtEIG-C29	FG156808	3.6

EB433973	2.8	Parsley PcPR1-3 mRNA for pathogenesis-related protein type B	CV016057	2.9

S44869	2.4	Nicotiana tabacum Endochitinase A precursor	EB441160	2.9

X12739	2.1	Nicotiana tabacum Pathogenesis-related protein R major form precursor	EB435759	2.8

TA14009_4097	0.5	Nicotiana tabacum Chitinase 134	TA12600_4097	2.8

EB425556	0.5	Arabidopsis thaliana beta-1,3-glucanase-related mRNA	EB451519	2.8

EH624302	0.5	Arabidopsis thaliana callose synthase 1 mRNA CALS1	EB445705	2.7

Defense related transcripts Flower	DV161729	2.1

FG167555	3.8	Nicotiana tabacum Avr9/Cf-9 rapidly elicited protein 111B (ACRE111B) AP2-DOMAIN	FG633784	2.0

AB041516	3.5	Nicotiana tabacum P-rich protein EIG-I30	EB680165	0.3

TA14524_4097	3.0	Nicotiana tabacum Avr9/Cf-9 rapidly elicited protein 65 (ACRE65) mRNA,	EB433693	0.4

FG640154	2.6	Nicotiana tabacum mRNA for basic pathogenesis-related protein Thaumatin	TA14058_4097	0.4

FG635113	2.5	Nicotiana tabacum Avr9/Cf-9 rapidly elicited protein 20 (ACRE20) mRNA; EF-hand calcium binding protein	EB439278	0.4

TA13004_4097	2.2	Nicotiana tabacum mRNA for hin1 gene: Harpin inducing protein	EB437158	0.5

TA15227_4097	2.1	Nicotiana tabacum Avr9/Cf-9 rapidly elicited protein 76; NDR1/HIN1	DW003496	0.5

AB127582	2.1	Nicotiana tabacum Harpin inducing protein 1-like 18 DOMAIN: LEA_2	EB438355	0.5

			EB438355	0.5

Stress related transcripts Leaf

Description

Tamarix Putative stress-responsive protein

Nicotiana tabacum 1-D-deoxyxylulose 5-phosphate synthase mRNA (DXS1)

Arabidopsis thaliana cold-regulated 413-plasma membrane 2 mRNA COR413-PM2

Solanum lycopersicum dxs2 gene for 1-deoxy-D-xylulose 5-phosphate synthase

Ipomoea nil In04 mRNA for caffeoyl-CoA O-methyltransferase

Solanum tuberosum Low temperature and salt responsive protein

Solanum lycopersicum geranylgeranyl pyrophosphate synthase 1 (GGPS1)

Vitis vinifera RD22-like protein mRNA

Arabidopsis thaliana snf1-related protein kinase 2.2, SNRK2.2

Solanum lycopersicum anthocyanin acyltransferase mRNA, Jasmonic acid inducible

Arabidopsis thaliana SIP3 (SOS3-INTERACTING PROTEIN 3)

Arabidopsis thaliana AFP1 (ABI FIVE BINDING PROTEIN)

Ipomoea nil CHS-D mRNA for chalcone synthase

Nicotiana tabacum NtERD10B mRNA for dehydrin

Ricinus communis leuco-anthocyanidin dioxygenase mRNA

Ricinus communis Salt-tolerance protein

Arabidopsis thaliana ATHK1 (histidine kinase 1/ osmosensor)

Catharanthus roseus cold inducible histidine kinase 1 (iK1) mRNA


n = 136	Total	Possible or specific OA diagnosis on GP request

		n (%)	ORa (95% CI)

Male	62	20 (32%)	1.00


Province	City	PCR-confirmedP. falciparum(N)

Khyber Pakhtunkhwa	Bannu	39

 	Hangu	19

 	Peshawar	4

 	Thal	29

Punjab	Bhakkar	1

 	Lahore	1

 	Mianwali	28

 	Muzaffarghar	13

 	Rawalpindi	0

Balochistan	Quetta	26

 	Zhob	7

Sindh	Hyderabad	0

 	Karachi	2

Capital	Islamabad	2

Total	 	171

Province	City	PCR-confirmedP. falciparum(N)

	Rawalpindi	0

Balochistan	Quetta	26

	Zhob	7

Sindh	Hyderabad	0

	Karachi	2

Capital	Islamabad	2

Total		171


Animal group	Number ofhemispheres used	MaxPs of activation evoked byF and revF stimulation	Comparison between sound types

F	revF	Type of test	p values

Trained	12	0.212 ± 0.063	0.116 ± 0.029	t test	8.74E-05

Naïve	12	0.199 ± 0.060	0.114 ±0.026	t test	1.97E-04


Rank	Tissues	Different developing flowers

	Gene name	Coefficient of correlation (r)	p-value	Gene name	Coefficient of correlation (r)

1	EF1-α	0.91	0.004	FAD	0.99

2	RPL3	0.90	0.005	EF1-α	0.99

3	18S	0.84	0.017	EF1-γ	0.95

4	ACT5	0.80	0.031	ACT5	0.95

5	FAD	0.79	0.034	NAC	0.94

6	NAC	0.62	0.139	ACT7	0.93

7	EF1-γ	0.62	0.141	RPL3	0.92

8	GAPDH	0.59	0.168	GAPDH	0.88

9	UBC	0.51	0.241	18S	0.83

10	ACT7	0.42	0.350	UBC	0.33


Location	X	Y	Z	Extent	Z-value

Univariate effect of degradation [((NV + SW)/2) > CL]

Left inferior frontal gyrus (p. Opercularis)	−54	10	20	555	3.92

 Left precentral gyrus	−52	8	30		3.86

 Left precentral gyrus	−46	2	28		3.80

Multivariate acoustic form coding

Left posterior STG	−63	−33	15	392	4.94

 Left mid-STG	−57	−12	4		4.62

 Left mid-anterior STG	−54	−6	−4		4.37

Right posterior STG	54	−42	15	254	4.13

 Right anterior STG	57	12	−8		3.99

 Right supramarginal Gyrus	54	−36	26		3.83

Multivariate syllable identity coding

Left mid-posterior left STG	−63	−24	8	303	4.59

 Left mid-STG	−48	−15	0		4.38

 Left posterior STS	−57	−39	8		4.21

Right posterior STG	69	−30	11	172	4.44

 Right posterior STG	57	−27	8		4.19

 Right mid-STG	63	−18	0		3.99

Left precentral gyrus	−51	0	41	83	4.39

 Left postcentral gyrus	−60	−3	38		3.97

Location	X	Y

Univariate effect of degradation [((NV + SW)/2) > CL]

Left inferior frontal gyrus (p. Opercularis)	−54	10

Left precentral gyrus	−52	8

Left precentral gyrus	−46	2

Multivariate acoustic form coding

Left posterior STG	−63	−33

Left mid-STG	−57	−12

Left mid-anterior STG	−54	−6

Right posterior STG	54	−42

Right anterior STG	57	12

Right supramarginal Gyrus	54	−36

Multivariate syllable identity coding

Left mid-posterior left STG	−63	−24

Left mid-STG	−48	−15

Left posterior STS	−57	−39

Right posterior STG	69	−30

Right posterior STG	57	−27

Right mid-STG	63	−18

Left precentral gyrus	−51	0

Left postcentral gyrus	−60	−3


Lineage	ρ (no. of crossovers/Mbp/generation) on chromosomea	% homoplastic SNPs	phi test P value


Author	Age and sex	Mechanism	Fielding type	Associated injuries	Duration to diagnosis	Reduction method and treatment	Results

Castel et al., 2001 [4]	41 M	Rugby injury	I	(—)	1 month	Reduction and Minerva jacket	Good

Fuentes et al., 2001 [5]	24 M	Suicidal jump	IV	Initial odontoid fracture only	1 month	C1-C2 fusion	Unknown

Kim et al., 2007 [8]	34 M	Fall down from high place	II	Lt superior facet fracture of C2	1 day	C1-C2 fusion	Good

Sinigaglia et al., 2008 [11]	26 F	Road traffic accident	I	(—)	45 days	Reduction and halo vest	Fair; because of cervical stiffness and headache

21 F	Road traffic accident	I	(—)	1 day	Reduction and halo vest	Good

29 M	Road traffic accident	I	(—)	1 day	Reduction and rigid collar	Good

Wang et al., 2008 [14]	44 F	Not described	I	(—)	6 months	Immobilization with halo vest	Poor; because of bilateral hand numbness

Goel et al., 2010 [6]	28 M	Fall down from high place	Not described	Odontoid fracture	1 day	Intraoperative facet manipulation	Good

Singh et al., 2009 [10]	25 F	Road traffic accident	I	(—)	0 day	Skull traction and halo brace	Good

Jeon et al., 2009 [7]	25 F	Road traffic accident	I	Thoracic fractures, alar ligament injury	5 days	Immobilization with Philadelphia brace	Good

Stenson, 2011 [12]	31 F	Falling backward	I	(—)	0 day	Immobilization with hard collar	Good

Marti et al., 2011 [9]	24 F	Stretching neck herself	I	(—)	1 day	Reduction and halo vest	Good

Venkatesan et al., 2012 [13]	20 F	Road traffic accident	I	(—)	0 day	Skull traction and hard collar	Fair; because of occipital pain

52 F	Road traffic accident	I	(—)	0 day	Halo traction and hard collar	Fair; because of occipital pain

Author	Age and sex	Mechanism	Fielding type	Associated injuries

Castel et al., 2001 [4]	41 M	Rugby injury	I	(—)

Fuentes et al., 2001 [5]	24 M	Suicidal jump	IV	Initial odontoid fracture only

Kim et al., 2007 [8]	34 M	Fall down from high place	II	Lt superior facet fracture of C2

Sinigaglia et al., 2008 [11]	26 F	Road traffic accident	I	(—)

21 F	Road traffic accident	I	(—)

29 M	Road traffic accident	I	(—)

Wang et al., 2008 [14]	44 F	Not described	I	(—)

Goel et al., 2010 [6]	28 M	Fall down from high place	Not described	Odontoid fracture

Singh et al., 2009 [10]	25 F	Road traffic accident	I	(—)

Jeon et al., 2009 [7]	25 F	Road traffic accident	I	Thoracic fractures, alar ligament injury

Stenson, 2011 [12]	31 F	Falling backward	I	(—)

Marti et al., 2011 [9]	24 F	Stretching neck herself	I	(—)

Venkatesan et al., 2012 [13]	20 F	Road traffic accident	I	(—)

52 F	Road traffic accident	I	(—)

Duration to diagnosis	Reduction method and treatment	Results

1 month	Reduction and Minerva jacket	Good

1 month	C1-C2 fusion	Unknown

1 day	C1-C2 fusion	Good

45 days	Reduction and halo vest	Fair; because of cervical stiffness and headache

1 day	Reduction and halo vest	Good

1 day	Reduction and rigid collar	Good

6 months	Immobilization with halo vest	Poor; because of bilateral hand numbness

1 day	Intraoperative facet manipulation	Good

0 day	Skull traction and halo brace	Good

5 days	Immobilization with Philadelphia brace	Good

0 day	Immobilization with hard collar	Good

1 day	Reduction and halo vest	Good

0 day	Skull traction and hard collar	Fair; because of occipital pain

0 day	Halo traction and hard collar	Fair; because of occipital pain


DDI, min.	Blood Loss (mls)			Hospital Stay (days)


Filter type	Central Frequency,f0	Rotation Variation Parameter,c	Half Central Bandwidth, bw	Number of Comb Teeth,n

Comblet filter: BSF	127.178 Hz	2%	1.272 Hz	100

Comblet filter: BPFI	308.242 Hz	2%	3.082 Hz	41

Comblet filter: BPFO	171.758 Hz	2%	1.718 Hz	74

Comblet filter: FTF	28.626 Hz	2%	0.286 Hz	447


S/N	Demographic characteristics	No of cases	Percentage	Chi square test	P Value

1	Age:a. up to 20 yearsb. 21-40 yearsc. 41 years and above	3417	5.8880.3913.75	79.411737.686253.6862

2	Parity:a. Para 0-1b. 2-4c. 5 and above	61629	11.7631.3756.86	59.647014.15681.9215	0.050.5

3	Booking Status:a. Bookedb. unbooked	1338	25.4974.50	24.5101	0.001

4	Referral status:a. Referred from other placesb. within hospital	3912	76.4723.52	28.5882	0.001

5	Level of medical person dealing:a. Paramedics LHV/Nursesb. medical officerc. resident doctord. senior resident	211893	41.1735.2917.645.88	3.17648.823542.705879.4111	 0.5 0.5


Deployment experience

Nondeployed

Deployed without combat exposures

Deployed with combat exposures

Smoking status

Never smoker

Past smoker

Current smoker

Problem drinking

No

Yes

Posttraumatic stress at baseline

No

Yes


Active sites of catalytic triad	HRV-C2	HRV2	EV71	PV	CVB4	CVB3	CVA16

Cys	105	106	110	109	110	110	110

His	34	18	21	20	21	18	21


Patient Group	P53 expression	χ2	P value

(No. of cases)	(+)	(-)

Grade I (14)	0	14	6.568	0.037

Grade II (10)	2	8

Grade III (16)	6	10

Patient Group	P53 expression	χ2	P value

(No. of cases)	(+)	(-)

Grade II (10)	2	8

Grade III (16)	6	10


Arlee	Clearwater	Skamania	Swanson	Whale rock


Exposure

Periconceptional CO

Categorized by quartiles (ppm)

0.09–0.59

0.60–0.80

0.81–1.02

1.03–3.73

Per 0.1-ppm increase

Periconceptional PM2.5

Categorized by quartiles (μg/m3)

5.9–8.7

8.8–10.1

10.2–11.4

11.5–15.1

Per 0.5-μg/m3 increase


Plant Age (Weeks)	Free PAA pmol (g FW)−1	Free IAA pmol (g FW)−1

Two weeks	98 ± 6.4	35 ± 2.7

Six weeks	23 ± 2	15 ± 1


Misclassification cost setting 5:1, post-pruning confidence 1%

	Classified as

Observed	SN	Non-SN

SN	0	34

Non-SN	0	815

Misclassification cost setting 10:1, post-pruning confidence 1%

	Classified as

Observed	SN	Non-SN

SN	8	26

Non-SN	66	749

Misclassification cost setting 25:1, post-pruning confidence 50%

	Classified as

Observed	SN	Non-SN

SN	31	3

Non-SN	18	797

Misclassification cost setting 5:1, post-pruning confidence 1%

Non-SN	66	749

Misclassification cost setting 25:1, post-pruning confidence 50%

	Classified as

Observed	SN	Non-SN

SN	31	3

Non-SN	18	797


Reference	Type of study	Subjects/number of studies	Results

Knutson et al. (72)	Cohort study and longitudinal, blood pressure and actigraphic sleep measured at 5-year intervals	578 AA and White	Reduced sleep predicted higher BP and adverse change in BP; sleep duration appeared to mediate racial differences in diastolic BP

Knutson (54)	National surveys, self-report	8 surveys conducted over 31 years	AAs consistently more likely to report short sleep duration than any other racial group

Vishnu et al. (73)	Cross-sectional survey, self-report	369,217 multi-ethnic US subjects	Strongest correlation between insufficient sleep and CHD found in AAs

Ruiters et al. (66)	Meta-analysis, variable methods including subjective and objective measures of sleep	14 studies	AAs had poorer sleep continuity and duration, less slow wave sleep, and a greater proportion of stage 2 sleep

Jean-Louis et al. (74)	National Health Interview Survey, 1977–2009, cross-sectional, face to face interviews	All ethnicities surveyed but restricted to Black and White participants	Among Black, very short sleepers 76% increased risk of overweight and 81% increased risk of obese

Halder et al. (68)	Cohort study using PSQI and in home polysomnography, correlation with % African genetic ancestry	70 AA and 101 European-American	% African ancestry correlated with lower percentage slow wave sleep but not sleep duration or efficiency

Curtis et al. (63)	Cross-sectional, actigraphic sleep	426 Midwestern US adults with oversampling of AAs	AA obtained less sleep and had lower sleep efficiency. Sleep duration predicted 41% of cardiometabolic risk factor variance

Johnson et al. (67)	Cross-sectional analysis, self-report	5,301 AAs in the Jackson Heart Study	54% reported <6 h sleep, 5% >9 h sleep. Social and environmental characteristics associated with sleep duration

Riestra et al. (70)	Cross-sectional analysis	2,962 AA participants	A SNP in the CLOCK gene associated with sleep duration after multifactorial adjustments

Reference	Type of study

Knutson et al. (72)	Cohort study and longitudinal, blood pressure and actigraphic sleep measured at 5-year intervals

Knutson (54)	National surveys, self-report

Vishnu et al. (73)	Cross-sectional survey, self-report

Ruiters et al. (66)	Meta-analysis, variable methods including subjective and objective measures of sleep

Jean-Louis et al. (74)	National Health Interview Survey, 1977–2009, cross-sectional, face to face interviews

Halder et al. (68)	Cohort study using PSQI and in home polysomnography, correlation with % African genetic ancestry

Curtis et al. (63)	Cross-sectional, actigraphic sleep

Johnson et al. (67)	Cross-sectional analysis, self-report

Riestra et al. (70)	Cross-sectional analysis

Subjects/number of studies	Results

578 AA and White	Reduced sleep predicted higher BP and adverse change in BP; sleep duration appeared to mediate racial differences in diastolic BP

8 surveys conducted over 31 years	AAs consistently more likely to report short sleep duration than any other racial group

369,217 multi-ethnic US subjects	Strongest correlation between insufficient sleep and CHD found in AAs

14 studies	AAs had poorer sleep continuity and duration, less slow wave sleep, and a greater proportion of stage 2 sleep

All ethnicities surveyed but restricted to Black and White participants	Among Black, very short sleepers 76% increased risk of overweight and 81% increased risk of obese

70 AA and 101 European-American	% African ancestry correlated with lower percentage slow wave sleep but not sleep duration or efficiency

426 Midwestern US adults with oversampling of AAs	AA obtained less sleep and had lower sleep efficiency. Sleep duration predicted 41% of cardiometabolic risk factor variance

5,301 AAs in the Jackson Heart Study	54% reported <6 h sleep, 5% >9 h sleep. Social and environmental characteristics associated with sleep duration

2,962 AA participants	A SNP in the CLOCK gene associated with sleep duration after multifactorial adjustments


 	Interest learning MBP (%)	Interest in participating in study of MBP during MHD (%)

Total (n = 89)	70	74

Age (years)

 18–34	100	100

 35–49	54	69

 50–64	71	74

 65–79	78	78

 ≥80 	46	46

Gender

 Female	74	74

 Males	66	75

Race

 White	54	65

 Black	76	74

 Other	71	100

Dialysis Vintage (years)

 <1	75	79

 1–4	68	74

 5–9	78	89

 ≥10	50	50

Ever used CAM use

 No	62	54

 Yes	74	87


Processing procedure	P(%)	R(%)	F(%)

(1): only candidate drugs replaced	75.9	68.7	71.5

(2): basic processing	77.5	72.3	74.8

(3): (2) + Following anaphora	76.9	76.5	76.7

(4): (3) + Pruned Sentences	78.4	76.2	77.3

Processing procedure	P(%)	R(%)	F(%)

(2): basic processing	77.5	72.3	74.8

(3): (2) + Following anaphora	76.9	76.5	76.7

(4): (3) + Pruned Sentences	78.4	76.2	77.3


	ASA Respondents (n = 209)	ESA Respondents (n = 165)

Answer Options	Response Percent	Response Percent

Blood pressure	88.5%	77.6%

Urine output	83.3%	77.0%

Clinical experience	77.5%	64.8%

Central venous pressure	70.8%	64.2%

Cardiac output	49.3%	53.3%

Pulse Pressure Variation or Systolic Pressure Variation	45.0%	55.8%

Transesophageal echocardiography	43.5%	28.5%

Pulmonary capillary wedge pressure	38.8%	24.2%

Plethysmographic Waveform Variation	25.4%	25.5%

Stroke Volume Variation	19.1%	36.4%

Mixed venous saturation (ScvO2)	18.7%	21.8%

Global end diastolic volume	10.5%	17.0%

Central venous saturation (SvO2)	10.0%	34.5%


	A MSC	BM MSC	COMMON

INHIBITION OF MMP	A2M, MMP2, TIMP1, TIMP2	A2M, MMP2, TIMP2	A2M, MMP2, TIMP2

EPITHELIAL ADHERENS JUNCTION	ACTN1, ACTN4, ACTR2, MYH9, TUBA1C, TUBB, VCL	ACTN1, ACTN4, ACTR2, ARPC3, IQGAP1, MYH9, TUBB, VCL	ACTN1, ACTN4, ACTR2, MYH9, TUBB, VCL

REMODELING OF EPITHELIAL ADHERENS JUNCTION	ACTN1, ACTN4, ACTR2, TUBA1C, TUBB, VCL	ACTN1, ACTN4, ACTR2, IQGAP1, NME1, TUBB, VCL	ACTNI, ACTN4, ACTR2, TUBB, VCL

GERM CELL SERTOLI JUNCTION	A2M, ACTN1, ACTN4, TUB1AC, TUBB, VCL	A2M, ACTN1, ACTN4, CFL1, IQGAP1, TUBB, VCL	A2M, ACTN1, ACTN4, TUBB, VCL

ACTIN CYTOSKELETON	ACTN1, ACTN4, ACTR2, EZR, MSN, MYH9, PFN1, TLN1, VCL	ACTN1, ACTN4, ARPC3, CFL1, FN1, IQGAP1, MSN, PFN1, RDX, VCL	ACTN1, ACTN4, MSN, PFN1, VCL

HEPATIC FIBROSIS	A2M, COL1A1, COL1A2, COL3A1, COL6A2, FN1, IGFBP3, MMP2, MYH9, SERPINE1, TIMP1, TIMP2	A2M, COL1A1, COL1A2, COL3A1, FN1, IGFBP3, MMP2, MYH9, SERPINE1, TIMP2	A2M, COL1A1, COL1A2, COL3A1, FN1, IGFBP3, MMP2, MYH9, SERPINE1, TIMP2

PROTEIN UBIQUITINATION	HSP90AA1, HSP90AB1, HSP90B1, HSPA5, HSPA8, HSPB1, HSPD1, PSMA1, PSMA3, PSMA5, PSMA6	HSP90AA1, HSP90AB1, HSP90B1, HSPA4, HSPA5, HSPA8, HSPB1, HSPD1, PSMA5, PSMB1, PSMB4, PSMB5, PSMB6	HSP90AA1, HSP90AB1, HSP90B1, HSPA8, HSPD1, PSMA5

RHOA SIGNALING	ACTR2, EZR, MSN, PFN1	ACRT2, ARPC3, CFL1, MSN, PFN1	ACTR2, MSN, PFN1

LEUCOCYTE EXTRAVASATION	ACTN1, ACTN4, EZR, GNAI2, MMP2, MSN, TIMP1, TIMP2, VCL	ACTN1, ACTN4, MMP2, MSN, RDX, TIMP2, VCL	ACTN1, ACTN4, MMP2, MSN, TIMP2, VCL

	A MSC

INHIBITION OF MMP	A2M, MMP2, TIMP1, TIMP2

EPITHELIAL ADHERENS JUNCTION	ACTN1, ACTN4, ACTR2, MYH9, TUBA1C, TUBB, VCL

REMODELING OF EPITHELIAL ADHERENS JUNCTION	ACTN1, ACTN4, ACTR2, TUBA1C, TUBB, VCL

GERM CELL SERTOLI JUNCTION	A2M, ACTN1, ACTN4, TUB1AC, TUBB, VCL

ACTIN CYTOSKELETON	ACTN1, ACTN4, ACTR2, EZR, MSN, MYH9, PFN1, TLN1, VCL

HEPATIC FIBROSIS	A2M, COL1A1, COL1A2, COL3A1, COL6A2, FN1, IGFBP3, MMP2, MYH9, SERPINE1, TIMP1, TIMP2

PROTEIN UBIQUITINATION	HSP90AA1, HSP90AB1, HSP90B1, HSPA5, HSPA8, HSPB1, HSPD1, PSMA1, PSMA3, PSMA5, PSMA6

RHOA SIGNALING	ACTR2, EZR, MSN, PFN1

LEUCOCYTE EXTRAVASATION	ACTN1, ACTN4, EZR, GNAI2, MMP2, MSN, TIMP1, TIMP2, VCL

BM MSC	COMMON

A2M, MMP2, TIMP2	A2M, MMP2, TIMP2

ACTN1, ACTN4, ACTR2, ARPC3, IQGAP1, MYH9, TUBB, VCL	ACTN1, ACTN4, ACTR2, MYH9, TUBB, VCL

ACTN1, ACTN4, ACTR2, IQGAP1, NME1, TUBB, VCL	ACTNI, ACTN4, ACTR2, TUBB, VCL

A2M, ACTN1, ACTN4, CFL1, IQGAP1, TUBB, VCL	A2M, ACTN1, ACTN4, TUBB, VCL

ACTN1, ACTN4, ARPC3, CFL1, FN1, IQGAP1, MSN, PFN1, RDX, VCL	ACTN1, ACTN4, MSN, PFN1, VCL

A2M, COL1A1, COL1A2, COL3A1, FN1, IGFBP3, MMP2, MYH9, SERPINE1, TIMP2	A2M, COL1A1, COL1A2, COL3A1, FN1, IGFBP3, MMP2, MYH9, SERPINE1, TIMP2

HSP90AA1, HSP90AB1, HSP90B1, HSPA4, HSPA5, HSPA8, HSPB1, HSPD1, PSMA5, PSMB1, PSMB4, PSMB5, PSMB6	HSP90AA1, HSP90AB1, HSP90B1, HSPA8, HSPD1, PSMA5

ACRT2, ARPC3, CFL1, MSN, PFN1	ACTR2, MSN, PFN1

ACTN1, ACTN4, MMP2, MSN, RDX, TIMP2, VCL	ACTN1, ACTN4, MMP2, MSN, TIMP2, VCL


Parameters	Case report [2]	Case report [3]	Our case report

Age	76 years	55 years	55 years

Circumcision	Uncircumcised	Delayed circumcision	Infantile circumcision

Site of stricture	Bulbar urethral stricture	Bulbar urethral stricture	Penile and bulbar urethral strictures

Time to develop malignancy	4 months	3 months	5 years

Presentation	Ulcerative lesion at glans penis	Penile periurethral mass	Ventral penile masses involving glans and whole exteriorised urethra, with associated scrotal wall changes

Treatment	Partial penectomy	Total penectomy	Total penectomy

Parameters	Case report [2]	Case report [3]	Our case report

Age	76 years	55 years	55 years

Circumcision	Uncircumcised	Delayed circumcision	Infantile circumcision

Site	Bulba	B	Peni

Parameters	Case report [2]	Case report [3]	Our case report

 of stricture	r urethral stricture	ulbar urethral stricture	le and bulbar urethral strictures

Time to develop malignancy	4 months	3 months	5 years

Presentation	Ulcerative lesion at glans penis	Penile periurethral mass	Ventral penile masses involving glans and whole exteriorised urethra, with associated scrotal wall changes

Treatment	Partial penectomy	Total penectomy	Total penectomy


Area	Bjørndalen	Sverdrup

Samples	Bd1	Bd2	Bd3	Bd4	Sv1, Sv2

Type	Spring water	Thaw water	Mix upstream	Mix downstream	Mat and sediment

pH	2.8	6.2	3.5	3.8	2.3

°C (water)	9	7	7	7	4

°C (air)	6	6	6	6	4

Na	3.1	2.5	3	2.8	42

K	1.1	0.5	1.6	1.3	0.2

Zn	0.3	Na	0.1	0.07	5.1

Ni	0.1	Na	0.03	0.02	1.3

Mg	5.4	1.3	2.6	2.3	145

Ca	Na	Na	Na	Na	10

Mn	0.4	Na	0.2	0.1	9.7

Cu	0.03	Na	Na	Na	0.8

Al	3.4	Na	1.8	0.9	76

Fe total	15	Na	2	2	883

Fe2+	9	Na	1	1	183

Fe3+	6	Na	1	1	700

SO42−	110	10	54	32	1543

Area	Bjørndalen

Samples	Bd1

Type	Spring water

pH	2.8

°C (water)	9

°C (air)	6

Na	3.1

K	1.1

Zn	0.3

Ni	0.1

Mg	5.4

Ca	Na

Mn	0.4

Cu	0.03

Al	3.4

Fe total	15

Fe2+	9

Fe3+	6

SO42−	110


Samplelabel	Addedeuropium(%wt)	Ca content(at%)	P content(at%)	Eu content(at%)	Ca+Eu/Pratio

HAP	0	6.96	5.14	0	1.35


	Total types	Total tokens	TTR

Proper nouns (Sem1)	699	9,516	0.073

Basic level count nouns (Sem2)	2,675	25,369	0.105

Basic level mass nouns (Sem3)	288	2,655	0.108

Action words (Sem4a)	228	1,419	0.161

Non-basic level words (Sem4b)	1,507	12,618	0.119


	N	%

Mean Age = 37.5 (S.D.11)

Citizenship

 Greek	77	76.2

 Other	24	23.8

Marital status

 Unmarried	53	52.5

 Married	19	18.8

 Divorced	21	20.8

 Widow	8	7.9

Children

 Yes	62	61.4

 No	39	38.6

Occupation before detention

 Employee	59	58.4

 Student	2	2.0

 Unemployed	26	25.7

 Pensioner	3	3.0

 Housework	9	8.9

 Other	2	2.0

Education level

 Compulsory	36	35.6

 Secondary	32	31.7

 Tertiary	24	23.8

 Postgraduate	9	8.9

	N	%

Mean Age = 37.5 (S.D.11)

Citizenship

Greek	77	76.2

Other	24	23.8

Marital status

Unmarried	53	52.5

Ma		1

	N	%

rried	19	8.8

Divorced	21	20.8

Widow	8	7.9

Children

Yes	62	61.4

No	39	38.6

Occupation before detention

Employee	59	58.4

Student	2	2.0

Unemployed	26	25.7

Pensioner	3	3.0

Housework	9	8.9

Other	2	2.0

Education level

Compulsory	36	35.6

Secondary	32	31.7

Tertiary	24	23.8

Postgraduate	9	8.9


Category	Clinical attachment level (CAL)	Probing pocket depth (PD)

Severe periodontitis	≥ 2 interdental sites with CAL ≥ 6 mm (not on same tooth) and	≥ 1 interdental site with PD ≥ 5 mm

Moderate periodontitis	≥ 2 interdental sites with CAL ≥ 4 mm (not on same tooth) or	≥ 2 interdental sites with PD ≥ 5 mm (not on same tooth)

No-or-mild periodontitis	Neither “moderate” nor “severe” periodontitis


Target	Accession Number	Forward Primer	Reverse Primer

Cyp2a4	NM_009997	GGAAGACGAACGGTGCTTTC	CCCGAAGACGATTGAGCTAATG

Cyp3a11	NM_007818	CGCCTCTCCTTGCTGTCACA	CTTTGCCTTCTGCCTCAAGT

Cyp2c37	NM_010001	ATACTCTATATTTGGGCAGG	GTTCCTCCACAAGGCAAC

Cyp2c39	NM_010003	GGAGACAGAGCTGTGGC	TAAAAACAATGCCAAGGCCG

Cyp2d22	NM_019823	GGGCCTTTGTTACCATGTTGG	TACTCGGCGCTGCACATCTG

β-actin	NM_007393	TGTTACCAACTGGGACGACA	GGGGTGTTGAAGGTCTCAAA


Surveillance site	Diarrhoea cases	Total

Non-diarrhoea cases	Rotavirusdiarrhoea	Cholera	Non-rotavirus and non-cholera diarrhoea

No.	%	No.	%	No.	%	No.	%

Bakerganj	163	63.7	31	12.1	27	10.5	35	13.7	256

Mathbaria	163	60.0	38	14.0	23	8.5	48	17.7	272

Total	326	61.7	69	13.1	50	9.5	83	15.7	528

Surveillance site	Diarrhoea cases	Total

Non-diarrhoea cases	Rotavirusdiarrhoea	Cholera	Non-rotavirus and non-cholera diarrhoea

No.	%	No.	%	No.	%	No.	%

Bake	163		3	1	2	10.	3	13.	25


	Total	Male sex	Female sex

Normouricemia (n = 1749)	Hyperuricemia (n = 393)	Normouricemia (n = 954)	Hyperuricemia (n = 238)	Normouricemia (n = 795)	Hyperuricemia (n = 155)

At 1-year

CAD	15	5	10	3	5	2

Congestive heart failure	4	2	2	1	2	1

Stroke	6	2	3	1	3	1

Peripheral vascular disease	0	1	0	0	0	1

At 2-year

CAD	25	8	16	5	9	3

Congestive heart failure	6	3	3	2	3	1

Stroke	11	2	6	1	5	1

Peripheral vascular disease	2	2	1	1	1	1

At 3-year

CAD	31	13	18	8	13	5

Congestive heart failure	15	5	9	3	6	2

Stroke	13	6	8	4	5	2

peripheral vascular disease	8	3	5	2	3	1

At 4-year

CAD	39	16	22	9	17	6

Congestive heart failure	16	6	10	4	6	2

Stroke	18	9	11	6	7	3

Peripheral vascular disease	11	5	7	4	4	1

At 5-year

CAD	44	17	26	11	18	7

Congestive heart failure	21	7	13	5	8	2

Stroke	23	13	13	8	10	5

Peripheral vascular disease	12	6	7	4	5	2

Cumulative Numbers of major CVD events over 5 years

CAD	154 (8.8%)	59 (15.0%)	92 (9.7 %)	36 (15.1%)	62 (7.8%)	23 (14.8%)

Congestive heart failure	62 (3.6%)	23 (5.9%)	37 (3.9%)	15 (6.1%)	25 (3.2%)	8 (5.2%)

Stroke	73 (4.2%)	32 (8.1%)	41 (4.3%)	20 (8.2%)	30 (3.8%)	12 (7.7%)

Peripheral vascular disease	33 (1.9%)	17 (4.6%)	20 (2.1%)	11 (4.6%)	13 (1.6%)	6 (3.7%)


	ASD (n = 24)	Controls (n = 18)	Statistics

Age	40.54 ± 10.279	37.17 ± 10.983	p = 0.313

Intelligence quotient	114.29 ± 15.213	113.00 ± 13.920	p = 0.779

Gender	12 m:12 f	8 m:10 f	p = 0.721

Nicotine	2.292 ± 5.894	2.222 ± 6.691	p = 0.972

Autism-spectrum quotient	39.08 ± 6.386	12.94 ± 5.504	p < 0.001

Empathy quotient	17.38 ± 9.523	47.94 ± 9.710	p < 0.001

Wender Utah Rating Scale	33.75 ± 16.690	8.72 ± 7.954	p < 0.001

Beck Depression Inventory score	17.25 ± 12.365	3.22 ± 4.236	p < 0.001

Level of education	Low school degree, 1 (4.2%)	Low school degree, 0 (0%)

Medium school degree, 3 (12.5%)	Medium school degree, 3 (16.7%)

High school degree, 9 (37.5%)	High school degree, 6 (33.3%)

University degree, 9 (37.5%)	University degree, 9 (50%)

Other, 2 (8.3%)	Other, 0 (0%)

Occupational situation	Full-time employed, 13 (54.2%)	Full-time employed, 7 (38.9%)

Part-time employment, 4 (16.7%)	Part-time employment, 4 (22.2%)

In vocational training/studying, 1 (4.2%)	In vocational training/studying, 7 (38.9%)

Pension, 1 (4.2%)	Pension, 0 (0%)

Unemployed, 4 (16.7%)	Unemployed, 0 (0%)

Other, 1 (4.2%)	Other, 0 (0%)

Psychiatric medication (in the last 3 months)	No, 11	No, 18

AD, 6	AD, 0

NL, 1	NL, 0

AD + NL, 5	AD + NL, 0

AD + MPH, 1	AD + MPH, 0

	ASD (n = 24)	Controls (n = 18)	Statistics

Age	40.54 ± 10.279	37.17 ± 10.983	p = 0.313

Intelligence quotient	114.29 ± 15.213	113.00 ± 13.920	p = 0.779

Gender	12 m:12 f	8 m:10 f	p = 0.721

Nicotine	2.292 ± 5.894	2.222 ± 6.691	p = 0.972

Autism-spectrum quotient	39.08 ± 6.386	12.94 ± 5.504	p < 0.001

Empathy quotient	17.38 ± 9.523	47.94 ± 9.710	p < 0.001

Wender Utah Rating Scale	33.75 ± 16.690	8.72 ± 7.954	p < 0.001

Beck Depression Inventory score	17.25 ± 12.365	3.22 ± 4.236	p < 0.001

Level of education	Low school degree, 1 (4.2%)	Low school degree, 0 (0%)

Medium school degree, 3 (12.5%)	Medium school degree, 3 (16.7%)

High school degree, 9 (37.5%)	High school degree, 6 (33.3%)

University degree, 9 (37.5%)	University degree, 9 (50%)

Other, 2 (8.3%)	Other, 0 (0%)

Occupational situation	Full-time employed, 13 (54.2%)	Full-time employed, 7 (38.9%)

Part-time employment, 4 (16.7%)	Part-time employment, 4 (22.2%)

In vocational training/studying, 1 (4.2%)	In vocational training/studying, 7 (38.9%)

Pension, 1 (4.2%)	Pension, 0 (0%)

Unemployed, 4 (16.7%)	Unemployed, 0 (0%)

Other, 1 (4.2%)	Other, 0 (0%)

Psychi	No, 11	No, 18

AD, 6	AD, 0

NL	NL,

atric medication (in the last 3 months)	, 1	 0

AD + NL, 5	AD + NL, 0

AD + MPH, 1	AD + MPH, 0


Cytological diagnosis	Frequency (n)	Percentage (%)

Chronic granulomatous inflammation	20	27.0%

Chronic sialadenitis	25	33.7%

Acute on chronic sialdenitis	22	29.7%

Benign cystic lesion	7	9.4%

Total	74	39.5%


Plasmid	Properties	Source/Reference

pRS316	Yeast centromeric plasmid. URA3 marker.	[52]

pRS316[PPHO84-GFP-TPHO84] (pRUL1336)	pRS316 containing the PHO84 promoter (600 bp), GFP and the PHO84 terminator (436 bp)	This study

pRS316[PCYC1-GFP-TCYC1] (pRUL1339)	pRS316 containing the CYC1 promoter (300 bp), GFP and the CYC1 terminator (220 bp)	This study

pRS316[PSPL2-GFP-TSPL2] (pRUL1354)	pRS316 containing the SPL2 promoter (647 bp), GFP and the SPL2 terminator (324 bp)	This study

pUG6	Plasmid containing the KAN.MX casette for gene disruptions	[53]

pUG36	Centromeric plasmid to make N-terminal GFP fusions.	Güldener and Hegemann, unpublished

pRS305	Yeast integration plasmid. LEU2 marker.	[52]

pRS305[PPHO84-GFP-TPHO84] (pRUL1359)	pRS305 containing the PHO84 promoter (600 bp), GFP and the PHO84 terminator (436 bp)	This study

pRS305[PCYC1-GFP-TCYC1] (pRUL1360)	pRS305 containing the CYC1 promoter (300 bp), GFP and the CYC1 terminator (220 bp)	This study

pRS313	Yeast centromeric plasmid. HIS3 selection marker.	[52]

pRS313[PHO4](pRUL1334)	pRS313 containing PHO4	[7]

pRS313[BMH1] (pRUL1330)	pRS313 containing a 3.2 kb genomic DNA fragment with BMH1	I.G. Anemaet, unpublished results

pRS305[PHO4] (pRUL1358)	pRS305 containing PHO4	This study

YCplac33	Yeast centromeric plasmid. URA3 marker	[54]

YCplac33[BMH1]	YCplac33 with a 3.2 kb genomic DNA fragment with BMH1	[55]

Plasmid	Properties	Source/Reference

pRS305	Yeast integration plasmid. LEU2 marker.	[52]

pRS305[PPHO84-GFP-TPHO84] (pRUL1359)	pRS305 containing the PHO84 promoter (600 bp), GFP and the PHO84 terminator (436 bp)	This study

pRS305[PCYC1-GFP-TCYC1] (pRUL1360)	pRS305 containing the CYC1 promoter (300 bp), GFP and the CYC1 terminator (220 bp)	This study

pRS313	Yeast centromeric plasmid. HIS3 selection marker.	[52]

pRS313[PHO4](pRUL1334)	pRS313 containing PHO4	[7]

pRS313[BMH1] (pRUL1330)	pRS313 containing a 3.2 kb genomic DNA fragment with BMH1	I.G. Anemaet, unpublished results

pRS305[PHO4] (pRUL1358)	pRS305 containing PHO4	This study

YCplac33	Yeast centromeric plasmid. URA3 marker	[54]

YCplac33[BMH1]	YCplac33 with a 3.2 kb genomic DNA fragment with BMH1	[55]


	N	%

Clinic location

 Rural	18	60

 Urban	5	17

 Peri-urban	7	23

Clinic type

 Quaternary/tertiary	1	3

 Secondary	1	3

 Primary	28	93

Public/private

 Public	27	90

 Private	0	0

 Mixed	3	10

NGO support

 None	17	57

 One	5	17

 Multiple	8	26

Year of pMTCT initiation

 Before 2005	5	17

 Between 2006 and 2008	21	70

 After 2008	4	13

Other characteristics	Mean	Median

 Distance to reference laboratory (km)	22	16

 Catchment population (people)	27,774	19,644

 No. 1st ANC visits in the last 6 months	674	468

 No. institutional births in the last 6 months	482	257

 No. post-partum visits in the last 6 months	418	189


Exposure

Serumb

CB 28+52+101

CB-153

Di-ortho PCB

Mono-ortho PCB TEQ

p,p'-DDE

Mother's milk exposurec

CB 28+52+101

CB-153

Di-ortho PCB

Mono-ortho PCB TEQ

p,p'-DDE


Profession	Round 1	Round 2	Round 3

P-HEMS doctors	21	16	15

P-HEMS nurses	14	12	12

EMS nurses	28	27	26

Dispatch centre operators	14	12	11

Trauma surgeons	22	24	21

Total respondents	83	79	71


		Hierarchical clustering	CCA	TribeMCL	Spectral clustering

Cluster count	Significant	243	243	245	235

	All	293	307	332	308

	Ratio	0.829	0.792	0.738	0.763

Total cluster size	Significant	1,166	1,858	3,600	4,863

	All	1,396	2,144	4,047	5,380

	Ratio	0.835	0.866	0.889	0.903

		Hierarchical clustering	CCA	TribeMCL	Spectral clustering

	Ratio	0.835	0.866	0.889	0.903


Primer name	Primer sequence (5′–3′)

Block-E1	CTACAAATCTTGTTACGCGGTATTA

argX-hisR 5′ intergenic region	CAGCTCAAGCGCCGGGACTA

argX-hisR centre intergenic region	TATTACTACCACCGCAGC

Block-E2	TTGTCACAACTTCTAATAA

Block-E3	TTTTAGTTCAATTCTTTAAAGTCG

Block-E4	AATACTGCTTTTTGAATTTTTAG

Primer name	Primer sequence (5′–3′)

Block-E1	CTACAAATCTTGTTACGCGGTATTA

argX-hisR 5′ intergenic region	CAGCTCAAGCGCCGGGACTA

ar	TA

gX-hisR centre intergenic region	TTACTACCACCGCAGC

Block-E2	TTGTCACAACTTCTAATAA

Block-E3	TTTTAGTTCAATTCTTTAAAGTCG

Block-E4	AATACTGCTTTTTGAATTTTTAG


Sample	Average Coverage after 1 s of SP	Coverage Standard Deviation after 1 s of SP	AR Coeff.	t (98%) [s]

S1300	60	3.3	0.92	4.28

S1400	73	2.6	1.31	2.98


Year Post Op	Glenoid Loosening	Bearing failure	Infection	Dislocation

1	0	0	0	0

2	0	1	0	0

3	0	0	0	1

4	0	0	0	0

Total	0	1	0	1


WHO region	ILO LABORSTA (farm worker average wage)	World Bank (average value per agricultural worker)	ILO (minimum wage)	US State Department (minimum wage)	Overall average – maximum of sourcesa	Overall average – minimum of sourcesa

AMRO	$6.90	$27.36	$5.27	$5.17	$27.36	$5.11

AFRO	$1.92	$8.18	$2.06	$2.16	$9.05	$1.01

EMRO	$4.84	$18.26	$3.19	$5.00	$18.26	$3.00

WPRO	$5.36	$9.06	$6.81	$6.74	$10.70	$4.98

SEARO	$1.80	$3.47	$1.77	$3.75	$4.04	$1.47

Average	$2.02	$5.10	$2.10	$3.42	$5.84	$1.50

WHO region	ILO LABORSTA (farm worker average wage)	World Bank (average value per agricultural worker)	ILO (minimum wage)	US State Department (minimum wage)	Overall average – maximum of sourcesa	Overall average – minimum of sourcesa

AMRO	$6.90	$27.36	$5.27	$5.17	$27.36	$5.11

AF	$1.92		$2.06		$9.	$1

WHO region	ILO LABORSTA (farm worker average wage)	World Bank (average value per agricultural worker)	ILO (minimum wage)	US State Department (minimum wage)	Overall average – maximum of sourcesa	Overall average – minimum of sourcesa

RO		$8.18		$2.16	05	.01

EMRO	$4.84	$18.26	$3.19	$5.00	$18.26	$3.00

WPRO	$5.36	$9.06	$6.81	$6.74	$10.70	$4.98

SEARO	$1.80	$3.47	$1.77	$3.75	$4.04	$1.47

Average	$2.02	$5.10	$2.10	$3.42	$5.84	$1.50


Subject	Gender	Age (yrs)	Etiology	Deafness (yrs)	CI side	CI experience (mos)	CVC (Ph%)	Implant

S1	Male	60	Familial	46	Left	160	93	Clarion CII

S2	Male	51	Progressive	25	Right	124	76	HiRes 90K

S3	Female	74	Familial	22	Left	114	93	HiRes 90K

S4	Male	58	Unknown	11	Right	31	93	HiRes 90K

S5	Male	67	Familial	67	Right	96	86	HiRes 90K

S6	Male	57	Familial	45	Right	174	96	Clarion CII

S7	Female	67	Meningitis	6	Left + right	73	88	HiRes 90K

S8	Female	43	Meningitis	5	Left + right	59	95	HiRes 90K

S9	Female	66	Unknown	35	Right	105	84	HiRes 90K

S10	Female	59	Type II Usher	4	Right	46	89	HiRes 90K

S11	Female	65	Meniere	25	Right	149	92	Clarion CII

Subject	Gender	Age (yrs)	Etiology	Deafness (yrs)	CI side	CI experience (mos)	CVC (Ph%)	Implant

S10	Female	59	Type II Usher	4	Right	46	89	HiRes 90K

S11	Female	65	Meniere	25	Right	149	92	Clarion CII


Item	Strongly Agree/Agree	QPCCC Subscale

	n	% 1 (95% CIs)

The staff at the hospital showed respect for me	191	91.0 (87.1–94.8)	Respectful communication

The staff at the hospital talked to me in a way I could understand	188	90.8 (86.9–94.8)	Respectful communication

The staff at the hospital showed respect for my family or friends	183	87.6 (83.1–92.0)	Respectful communication

The staff at the hospital gave me information about cancer that was easy to understand	183	87.1 (82.6–91.7)	Cancer information

The staff at the hospital gave me information about cancer and treatments to take home (e.g., booklets, websites)	180	86.1 (81.4–90.8)	Cancer information

During my treatment, staff at the hospital made sure I received the treatment I was meant to have	182	85.8 (81.2–90.5)	Treatment delivery

The doctors at the hospital explained to me the short-term side effects of each treatment option	175	84.5 (79.6–89.5)	Treatment decision-making

The doctors at the hospital explained to me all of the treatments I could have	175	83.7 (78.7–88.7)	Treatment decision-making

During my treatment, staff at the hospital had up-to-date information about my cancer care	173	83.2 (78.1–88.3)	Treatment delivery

During my treatment, staff at the hospital made sure I received treatment that was based on scientific knowledge	169	82.0 (76.8–87.3)	Treatment delivery

During my treatment, staff at the hospital gave me consistent information about my treatment	169	80.9 (75.5–86.2)	Treatment delivery

During my treatment, staff at the hospital co-ordinated my appointments so that I did not have to go to hospital more than necessary	168	80.0 (74.6–85.4)	Treatment delivery

Item	Strongly Agree/Agree	QPCCC Subscale

	n	% 1 (95% CIs)

During my treatment, staff at the hospital gave me consistent information about my treatment	169	80.9 (75.5–86.2)	Treatment delivery

During my treatment, staff at the hospital co-ordinated my appointments so that I did not have to go to hospital more than necessary	168	80.0 (74.6–85.4)	Treatment delivery


Place	Age (years)	Level of education (years of study)	Income (R$)

Average	95%CI	Average	95%CI	Average	95%CI

er places	.2	7–36.7		.6	1035.99	9.49


	Name	Screening	Intervention	Follow-up

	Duration	12 months	6 months	6 months

Visits	Time		Surgery	Days 1–3	Wk 2	Wk 4	Wk 8	Wk 12	Wk 16	Wk 20	Wk 24	Wk 48

Anamnesis	Anamnesis	X									X	X

Body weight	X			X	X	X	X	X	X	X	X

Anthropometry	X				X	X	X	X	X	X	X

Dietary assessment, BDI	X				X		X			X	X

Bone density	DEXA	X									X	X

Liver and microbiota	FibroScan and CAPTM	X				X		X			X	X

Stool samples	X				X		X			X	X

Biopsies	Liver, SAT, VAT		X

Supplementation	Loading dose			X	X	X

Maintenance dose					X	X	X	X	X	X	X

Blood parameter	Vitamin D	X			X	X	X	X	X	X	X	X

Biochemical	X			X	X	X	X	X	X	X	X

Liver	X				X		X			X	X

Inflammation	X			X	X	X	X	X	X	X	X

Insulin resistance	X			X	X	X	X	X	X	X	X

Bone turnover	X				X		X			X	X

Blood parameter	Liver	X		X		X			X	X

Inflammation	X	X	X	X	X	X	X	X	X

Insulin resistance	X	X	X	X	X	X	X	X	X

Bone turnover	X		X		X			X	X


Drug category	Drug name	Prescribed acutely	Prescribed on discharge

No.	%	No.	%

Antiplatelet drugs	Aspirin	521	37.0	670	47.7

Clopidogrel	50	3.6	66	4.7

Dipyridamole	< 10	< 1	13	0.9

Aggrenox	< 10	< 1	12	0.9

Fibrinolytic	Alteplase	< 10	< 1	n/a

Anticoagulants	Warfarin	16	1.1	49	3.5

Heparin (subcutaneous)	333	23.7	n/a

Heparin (low molecular weight)	44	3.1	32	2.3

Statins	Simvastatin, Atorvastatin	304	21.6	681	48.4

Drug category	Drug name	Prescribed acutely

No.	%

Antiplatelet drugs	Aspirin	521	37.0

Clopidogrel	50	3.6

Dipyridamole	< 10	< 1

Aggrenox	< 10	< 1

Fibrinolytic	Alteplase	< 10	< 1

Anticoagulants	Warfarin	16	1.1

Heparin (subcutaneous)	333	23.7

Heparin (low molecular weight)	44	3.1

Statins	Simvastatin, Atorvastatin	304	21.6


Boys

	Special	New	Fashionable

Biscuits and ice creams	65.3	18.7	44.6

Bread and pasta	80.0	8.3	31.7

Chocolate and snacks	64.3	22.6	49.0

Cold cuts	60.6	9.1	19.7

Dairy products	55.0	10.0	25.0

Eggs	80.0	10.0	20.0

Fat Meat	68.9	30.4	54.1

Filled cakes and sweets	72.2	14.8	50.9

Fish	75.0	0.0	50.0

Fried fish	50.0	37.5	12.5

Fried potatoes	80.2	33.7	60.4

Juices and drinks	56.3	34.4	46.9

Lean meet	58.0	4.3	26.1

Non-sweet fruits and cereals	69.2	23.1	30.8

Oils and condiments	32.9	9.2	26.3

Pizza	85.5	21.8	58.2

Sweet fruit	100.0	0.0	0.0

Vegetables	50.0	11.1	22.2

OVERALL	65.8	19.8	44.1

Girls

	Special	New	Fashionable

Biscuits and ice creams	61.1	13.7	35.8

Bread and pasta	55.5	7.8	15.6

Chocolate and snacks	64.1	26.4	47.3

Cold cuts	58.1	13.5	28.4

Dairy products	56.0	12.0	20.0

Eggs	57.1	14.3	28.6

Fat Meat	44.0	48.0	46.7

Filled cakes and sweets	67.0	24.7	37.1

Fish	20.0	0.0	0.0

Fried fish	25.0	100.0	25.0

Fried potatoes	68.6	34.3	50.5

Juices and drinks	60.0	42.9	60.0

Lean meet	67.8	11.9	30.5

Non-sweet fruits and cereals	35.7	7.1	35.7

Oils and condiments	41.4	8.1	25.2

Pizza	74.3	11.4	37.1

Sweet fruit	77.8	22.2	11.1

Vegetables	69.2	23.1	15.4

OVERALL	59.9	21.1	37.1


599C>T GPX1 (rs1050450)

BMI (kg/m2)	Before

After

SBP (mgHg)	Before

After

DBP (mgHg)	Before

After

TBARS (mg/dl)	Before

After

Glucose (mg/dl)	Before

After

Total cholesterol (mg/dl)	Before

After

LDL-C (mg/dl)	Before

After

Triglycerides (mg/dl)	Before

	After

Atherogenic index	Before

After


Phenotype	Frequency (n (%))	Genotype concordance (%)

HLA-B27-positiveα	rs4349859-positiveb	rs116488202-positive	rs4349859	rs116488202

Controls	Caucasian	9/117 (7.7)	9/117 (7.7)	9/117 (7.7)	100.0	100.0


Plant extracts	IC50 values (μg/mL) ± SD	Vitamin C equivalents for a 200 mg capsule (in g)

(1) Rosmarinus officinalis (McConnell's Blue)	3.48 ± 0.22	0.351

(2) Rosmarinus officinalis (Tuscan Blue)	10.84 ± 0.12	1.09

(3) Lavandula-x-intermedia (Margaret Roberts)	138.5 ± 4.0	14.0

(4) Lavandula spica 	125.5 ± 1.8	12.67

(5) Origanum vulgare 	26.43 ± 1.58	2.67

(6) Petroselinum crispum 	53.3 ± 2.63	5.38

(7) Laurus nobilis 	30.85 ± 0.48	3.12

(8) Thymus vulgaris 	36.13 ± 0.85	3.65

(9) Foeniculum vulgaris 	38.36 ± 0.76	3.88

(10) Capsicum annuum (Paprika)	63.06 ± 1.91	6.27

(11) Vitamin Ca	1.98 ± 0.01	—

Plant extracts	IC50 values (μg/mL) ± SD	Vitamin C equivalents for a 200 mg capsule (in g)

(1) Rosmarinus officinalis (McConnell's Blue)	3.48 ± 0.22	0.351

(2) Rosmarinus officinalis (Tuscan Blue)	10.84 ± 0.12	1.09

(3) Lavandula-x	138.5 ± 4.	14.0

-intermedia (Margaret Roberts)	0

(4) Lavandula spica	125.5 ± 1.8	12.67

(5) Origanum vulgare	26.43 ± 1.58	2.67

(6) Petroselinum crispum	53.3 ± 2.63	5.38

(7) Laurus nobilis	30.85 ± 0.48	3.12

(8) Thymus vulgaris	36.13 ± 0.85	3.65

(9) Foeniculum vulgaris	38.36 ± 0.76	3.88

(10) Capsicum annuum (Paprika)	63.06 ± 1.91	6.27

(11) Vitamin Ca	1.98 ± 0.01	—


	Standard low-fat diet	DHA low-fat diet	High saturated fat diet

N	18	20	19


Patient	Gender	Basal CD4+(cells/mm3)	HCV VL range (log10 UI/mL)†	Fibrosis grade (METAVIR score)	Response to IFN-based therapy	Sampling times∗

A	F	U	<2.78–6.5	0	R	0, 24 h, 4 wk, 12 wk, 24 wk, 48 wk, 72 wk

B	F	644	4.5–6.7	4	NR	0, 24 h, 4 wk, 12 wk, 24 wk

C	M	304	5.3–6.8	2	NR	0, 24 h, 4 wk, 12 wk, 24 wk

E	M	957	<2.78–6.1	3	NR	0, 24 h, 3 wk, 12 wk, 24 wk

G	M	376	<2.78–6.8	2	NR	0, 24 h, 4 wk, 12 wk, 24 wk, 48 wk, 72 wk

H	M	130	5.3–7.1	0	NR	0, 24 h, 4 wk, 24 wk

J	M	817	3.6–7.1	1	NR	0, 24 h, 4 wk, 12 wk, 24 wk


Disease location	Cases(n = 94)	Sensitivity(%)	Specificity(%)	PPV(%)	NPV(%)	Accuracy(%)

Endometriomas	57 (60.6%)	100	100	100	100	100

Bladder nodules	11 (11.7%)	90.9	100	100	98.8	98.9


	Phenolic Acid Intake

Q1 	Q2 	Q3	Q4 (Med


Item	Number of Patients	Percentage (%)

Gender	Male	127	59.1

Female	88	40.9

Age	<60	108	50.2

≥60	107	49.8

Smoking history	Yes	95	44.2

No	120	55.8

Disease staging	Stage IIIB	36	16.7

Stage IV	179	83.3

Therapy received	Chemotherapy	181	84.2

EGFR-TKI treatment	114	53.0

Item

Gender	Male

Female

Age	<60

≥60

Smoking history	Yes

No

Disease staging	Stage IIIB

Stage IV

Therapy received	Chemotherapy

EGFR-TKI treatment


Namea	Age	Regular medication prior to trial	Trial completion	Result of trial	Treatment decision

Standard vs heat retaining knee support – trials commencing December 2001 to February 2002

Ann	67	solpadol, meloxicam, amitryptiline	Completed	Heat retaining support beneficial	Continued use of heat retaining support

Mel	54	dihydrocodeine, co-dydramol, amitryptiline	Withdrew after 6 weeks – intolerance to supports	No further use of supports

Amber	49	no regular medication, occasional paracetamol	Completed	Heat retaining support beneficial	Continued use of heat retaining support

Lyn	54	rofecoxib, dihydrocodeine, paracetamol	Completed	No benefit from either support	No further use of supports

Pansyb	51	rofecoxib	Completed	No benefit from either support	No further use of supports

Diclofenac vs paracetamol – trials commencing September 2003 to October 2003

Pansyb	53	Rofecoxib	Withdrew after 6 weeks – diclofenac side-effect (stomach pains)	Returned to previous treatment

Rosie	31	Paracetamol	Withdrew after 2 weeks – diclofenac side-effect (mouth ulcers)	Returned to previous treatment

Jack	59	no regular medication	Completed	No benefit from either drug	No regular medication (paracetamol when necessary)

George	61	cod liver oil only	Completed	Diclofenac superior	Continued with diclofenac

Namea	Age	Regular medication prior to trial	Trial completion	Result of trial

Standard vs heat retaining knee support – trials commencing December 2001 to February 2002

Ann	67	solpadol, meloxicam, amitryptiline	Completed	Heat retaining support beneficial

Mel	54	dihydrocodeine, co-dydramol, amitryptiline	Withdrew after 6 weeks – intolerance to supports

Amber	49	no regular medication, occasional paracetamol	Completed	Heat retaining support beneficial

Lyn	54	rofecoxib, dihydrocodeine, paracetamol	Completed	No benefit from either support

Pansyb	51	rofecoxib	Completed	No benefit from either support

Diclofenac vs paracetamol – trials commencing September 2003 to October 2003

Pansyb	53	Rofecoxib	Withdrew after 6 weeks – diclofenac side-effect (stomach pains)

Rosie	31	Paracetamol	Withdrew after 2 weeks – diclofenac side-effect (mouth ulcers)

Jack	59	no regular medication	Completed	No benefit from either drug

George	61	cod liver oil only	Completed	Diclofenac superior

Treatment decision

Standard vs heat retaining knee support – trials commencing December 2001 to February 2002

Continued use of heat retaining support

No further use of supports

Continued use of heat retaining support

No further use of supports

No further use of supports

Diclofenac vs paracetamol – trials commencing September 2003 to October 2003

Returned to previous treatment

Returned to previous treatment

No regular medication (paracetamol when necessary)

Continued with diclofenac


Skin cancer	TGF-β	uPA/uPAR

BCC	−/+	?

SCC	++	++

Melanoma	−/+	++


Motif family	Heart	Sperm

E2F1	Hypo-methylated	Hypo-methylated

NFY1	Hypo-methylated	Hypo-methylated

YY11	Hypo-methylated	Hypo-methylated

MYCMAX1	Hypo-methylated	Hyper-methylated

NFKB1	Hypo-methylated	Hyper-methylated

AP1	Hypo-methylated	Hyper-methylated

NRSF2	Hypo-methylated	Neutral

SREBP3	Hypo-methylated	Neutral

SRF2	Hypo-methylated	Neutral

STAT4	Hypo-methylated	Neutral

TCF1	Hypo-methylated	Neutral

GATA1	Neutral	Hyper-methylated

NFE21	Neutral	Neutral

OCT5	Neutral	Neutral

SOX5	Neutral	Neutral

EP3005	Neutral	Neutral

TP536	Neutral	Neutral


 	Features or characteristics	Total

Diagnosed with infection in pregnancy	Infant with CRI but no CRS features at birth	3

Infant with CRI resulting in CRS	5

Diagnosed after birth	Infant with CRI resulting in CRS	7

Acquisition of rubella infection	Maternal infection acquired abroad	8

Maternal infection UK acquired	6

Place of infection not known	1

Maternal place of birth	Mother born abroad	14

Maternal place of birth not known	1

Reported features of 11 of 12 CRS casesb (more than one feature may be reported for each infant)	Thrombocytopaenia at birth	2

Sensorineural hearing loss	10

Eye defects	8

Failure to thrive	3

Heart defects	10

Developmental problems	3

Microcephaly	5

	Features or characteristics

Diagnosed with infection in pregnancy	Infant with CRI but no CRS features at birth

Infant with CRI resulting in CRS

Diagnosed after birth	Infant with CRI resulting in CRS

Acquisition of rubella infection	Maternal infection acquired abroad

Maternal infection UK acquired

Place of infection not known

Maternal place of birth	Mother born abroad

Maternal place of birth not known

Reported features of 11 of 12 CRS casesb (more than one feature may be reported for each infant)	Thrombocytopaenia at birth

Sensorineural hearing loss

Eye defects

Failure to thrive

Heart defects

Developmental problems

Microcephaly


Extraction methods	Abbreviation	Crude extract (mg/g herb)

Heat reflux extraction using water	HRE-W	297.4 ± 28.4

Microwave-assisted extraction using water	MAE-W	390.8 ± 16.6***

Ultrasonic extraction using ethanol (70 % vol/vol)	UE-E	327.4 ± 19.4

Ultrasonic extraction using water	UE-W	275.0 ± 9.0

Extraction methods

Heat reflux extraction using water

Microwave-assisted extraction using water

Ultrasonic extraction using ethanol (70 % vol/vol)

Ultrasonic extraction using water

Abbreviation	Crude extract (mg/g herb)

HRE-W	297.4 ± 28.4

MAE-W	390.8 ± 16.6***

UE-E	327.4 ± 19.4

UE-W	275.0 ± 9.0


Treatment	S. aureus NCTC 13297	P. aeruginosa NCTC 10781	Co-culture

	Concentration	Mean OD	Biofilm	Concentration	Mean OD	Biofilm	Concentration	Mean OD	Biofilm

Bacteria		0.1	Moderate		0.54	Strong		0.14	Moderate

BgAg	0.625%	0.04	Non-adherent	0.625%	0.08	Weak	0.625%	0.06	Weak

	0.15%	0.1	Moderate	0.15%	0.23	Strong	0.15%	0.09	Moderate

Bg	0.625%	0.11	Moderate	0.625%	0.07	Weak	0.625%	0.09	Moderate

	0.15%	0.1	Moderate	0.15%	0.5	Strong	0.15%	0.11	Moderate

Treatment	S. aureus NCTC 13297

	Concentration

Bacteria

BgAg	0.625%

	0.15%

Bg	0.625%

	0.15%

S. aureus NCTC 13297	P. aeruginosa NCTC 10781	Co-culture

Mean OD	Biofilm	Concentration	Mean OD	Biofilm	Concentration	Mean OD	Biofilm

0.1	Moderate		0.54	Strong		0.14	Moderate

0.04	Non-adherent	0.625%	0.08	Weak	0.625%	0.06	Weak

0.1	Moderate	0.15%	0.23	Strong	0.15%	0.09	Moderate

0.11	Moderate	0.625%	0.07	Weak	0.625%	0.09	Moderate

0.1	Moderate	0.15%	0.5	Strong	0.15%	0.11	Moderate


Source of variations	Degree of freedom	Mean square

pH	Exchangeable acidity	Exchangeable Al	Exchangeable Fe	Exchangeable Ca

Treatments	4	3.71∗	0.23∗	0.08∗	9.03∗	70.70∗

Time 	2	0.65∗	0.15∗	0.01∗	0.37∗	0.52∗

Treatments ∗ time	8	0.76∗	0.34∗	0.01∗	0.14∗	0.24∗

Error	30

Source of variations	Degree of freedom	Mean square

pH	Exchangeable acidity	Exchangeable Al	Exchangeable Fe	Exchangeable Ca

Treatments ∗ time	8	0.76∗	0.34∗	0.01∗	0.14∗	0.24∗

Error	30


EC identifier	Enzyme name	Pathway	Reference

2.1.3.3	Ornithine carbamoyltransferase	Arginine/Proline	Cook et al (2007)

2.3.1.57	Diamine N-acetyltransferase	Polyamines	Cook et al (2007)

2.6.99.2	Pyridoxine 5-phosphate synthase	Misc	Muller and Kappes (2007)

2.7.2.2	Carbamate kinase	Pyrimidine	Cook et al (2007)

3.5.3.6	Arginine deaminase	Arginine/Proline	Cook et al (2007)

3.5.4.2	Adenine deaminase	Purine	Chaudhary et al (2004)

4.2.1.60	3-Hydroxydecanoyl-[acp] dehydratase	Fatty-acid synthesis	Dautu et al (2008)

4.2.1.61	3-Hydroxydecanoyl-[acp] dehydratase	Fatty-acid synthesis	Dautu et al (2008)

4.2.1.75	Uroporphyrinogen-III synthase	Porphyrin	Seeber et al (2008)

4.2.1.99	2-Methylisocitrate dehydratase	MC cycle	Seeber et al (2008)

5.5.1.4	Inositol-3-phosphate synthase	Phospholipid	Smith et al (2007)

EC identifier	Enzyme name	Pathway	Reference

4.2.1.75	Uroporphyrinogen-III synthase	Porphyrin	Seeber et al (2008)

4.2.1.99	2-Methylisocitrate dehydratase	MC cycle	Seeber et al (2008)

5.5.1.4	Inositol-3-phosphate synthase	Phospholipid	Smith et al (2007)


Meeting/ Event (Date)	Alcohol industry	Tobacco industry

Informal Discussion meeting for Chairmen & Directors of Large Organisations held at BAT offices (1966)	Courage, Barclay Simmonds	BAT, Gallaher

Practical Skills of Managing People (1981)	Allied, Bass, Charrington, S&N	BAT

Practical Skills of Managing Event (1981)	Allied, Bass-Charrington, Scottish & Newcastle	BAT

Fermenters Symposium (1982)	Allied, Watney, Grand Met	BAT

CBI Conference, Seminar: Employee Involvement (1983)	Allied, Bass, Brewers’ Society, Grand Met, Lyons Tetley, Truman, Whitbread	BAT

Institute of Chemical Engineers (ICHEME) Meeting (1985)	Guinness, Watney, Nabisco	BAT

Minerva Public Relations Group UK Meeting (1988)	The Alcohol Duty Group	The Tobacco Duty Free Group

Statistics for Industry Ltd., Statistical Workshops (1991)	Allied, Bass, Guinness	Imperial, Rothmans

Advertising Association- Performance Monitoring Seminar (1994)	Carlsberg-Tetley, Allied-Lyons, Hiram Walker Group, United Distillers	BAT

Monitoring Advertising Performance Event (1998)	Guinness, Scottish Courage, IDV	BAT

Meeting/ Event (Date)	Alcohol industry

Informal Discussion meeting for Chairmen & Directors of Large Organisations held at BAT offices (1966)	Courage, Barclay Simmonds

Practical Skills of Managing People (1981)	Allied, Bass, Charrington, S&N

Practical Skills of Managing Event (1981)	Allied, Bass-Charrington, Scottish & Newcastle

Fermenters Symposium (1982)	Allied, Watney, Grand Met

CBI Conference, Seminar: Employee Involvement (1983)	Allied, Bass, Brewers’ Society, Grand Met, Lyons Tetley, Truman, Whitbread

Institute of Chemical Engineers (ICHEME) Meeting (1985)	Guinness, Watney, Nabisco

Minerva Public Relations Group UK Meeting (1988)	The Alcohol Duty Group

Statistics for Industry Ltd., Statistical Workshops (1991)	Allied, Bass, Guinness

Advertising Association- Performance Monitoring Seminar (1994)	Carlsberg-Tetley, Allied-Lyons, Hiram Walker Group, United Distillers

Monitoring Advertising Performance Event (1998)	Guinness, Scottish Courage, IDV

Tobacco industry

BAT, Gallaher

BAT

BAT

BAT

BAT

BAT

The Tobacco Duty Free Group

Imperial, Rothmans

BAT

BAT


Determinants	Odds ratio	Changeabilitya	Category	Target groupb

Demographic

Age >40 years	2.65	-	Not applicable	Not applicable

Chronic illness	3.37	-	Not applicable	Not applicable

Behavioural

Aware of personal risk for influenza infection	2.80	+	Knowledge	2

Aware of risk of infecting patients	2.54	+	Knowledge	2

‘Vaccination reduces risk of infecting patients’	3.68	+	Knowledge	2

‘Vaccination is useful despite the constant flow of visitors’	1.88	+	Knowledge	2

Aware of the contents of the Health Council’s Advice	2.41	+	Knowledge	2

‘HCWsc should get vaccinated to ensure continuity of care’	2.15	+	Common interest	3

‘HCWs should get vaccinated because of their duty to do no harm’	2.22	+	Common interest	3

‘People around me think it is important for me to get vaccinated’	1.74	+/-	Social impact	3

‘I would definitively get vaccinated if it was available at a convenient time’	28.91	+	Organizational	1,2,3

Determinants

Demographic

Age >40 years

Chronic illness

Behavioural

Aware of personal risk for influenza infection

Aware of risk of infecting patients

‘Vaccination reduces risk of infecting patients’

‘Vaccination is useful despite the constant flow of visitors’

Aware of the contents of the Health Council’s Advice

‘HCWsc should get vaccinated to ensure continuity of care’

‘HCWs should get vaccinated because of their duty to do no harm’

‘People around me think it is important for me to get vaccinated’

‘I would definitively get vaccinated if it was available at a convenient time’

Odds ratio	Changeabilitya	Category	Target groupb

Demographic

2.65	-	Not applicable	Not applicable

3.37	-	Not applicable	Not applicable

Behavioural

2.80	+	Knowledge	2

2.54	+	Knowledge	2

3.68	+	Knowledge	2

1.88	+	Knowledge	2

2.41	+	Knowledge	2

2.15	+	Common interest	3

2.22	+	Common interest	3

1.74	+/-	Social impact	3

28.91	+	Organizational	1,2,3


Rank	rs ID	pval	Gene Sym	Gene Name	SNP Function

1.0	rs10018625	0.001536	TAG ERROR	TAG ERROR	unknown, TAG ERROR

2.0	rs1047643	0.001603	FDFT1	Farnesyl-diphosphate farnesyltransferase 1	coding-synon

3.0	rs20541	0.001644	IL13	Interleukin 13	coding-nonsynon

4.0	rs2108622	0.0020374	CYP4F2	Cytochrom P450, family 4, subfamily F, polypeptide 2	coding-nonsynon

5.0	rs3759259	0.002362	STYK1	Protein kinase STYK1	coding-nonsynon

6.0	rs1801133	0.003251	MTHFR	5, 10-methylenetetrahydrofolate reductase (NADPH)	coding-nonsynon

7.0	rs2069456	0.003375	CDK5	Cyclin-dependent kinase 5	intron

8.0	rs1131532	0.005650	TNFSF10	Tumor necrosis factor (ligand) superfamily, member 10	coding-synon

9.0	rs882709	0.005965	SETX	senataxin	coding-nonsynon

10.0	rs4646421	0.007847	CYP1A1	Cytochrome P450, family 1, subfamily A, polypeptide 1	intron

11.0	rs1799969	0.008221	ICAM1	Intercellular adhesion molecule 1 (CD54), human rhinovirus receptor	coding-nonsynon

12.0	rs3822430	0.009157	SRD5A1	Steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1)	coding-synon

13.0	rs7903344	0.009471	CHUK	Conserved helix-loop-helix ubiquitous kinase	coding-nonsynon

14.0	rs13926	0.011531	TRAP1	TNF receptor-associated protein 1	coding-nonsynon

15.0	rs3172469	0.012006	BCL6	B-cell CCL/lymphoma 6 (zinc finger protein 51)	intron

16.0	rs215101	0.012028	ABCC1	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	intron, TagSNP:ABCC1

17.0	rs2227564	0.012246	PLAU	Plasminogen activator, urokinase	coding-nonsynon

18.0	rs3096057	0.012484	CSF1	Colony stimulating factor 1 (macrophage)	Promoter

19.0	rs6474491	0.013935	STAR	Steriodogenic acute regulator	Promoter

20.0	rs2066471	0.015231	MTHRF	5, 10-methlyenetetrahydrofolate reductase (NADPH)	intron

Rank	rs ID	pval	Gene Sym	Gene Name	SNP Function

1.0	rs10018625	0.001536	TAG ERROR	TAG ERROR	unknown, TAG ERROR

2.0	rs1047643	0.001603	FDFT1	Farnesyl-diphosphate farnesyltransferase 1	coding-synon

3.0	rs20541	0.001644	IL13	Interleukin 13	coding-nonsynon

4.0	rs2108622	0.0020374	CYP4F2	Cytochrom P450, family 4, subfamily F, polypeptide 2	coding-nonsynon

	rs3759259	0		Pr	c

5.0		.002362	STYK1	otein kinase STYK1	oding-nonsynon

6.0	rs1801133	0.003251	MTHFR	5, 10-methylenetetrahydrofolate reductase (NADPH)	coding-nonsynon

7.0	rs2069456	0.003375	CDK5	Cyclin-dependent kinase 5	intron

8.0	rs1131532	0.005650	TNFSF10	Tumor necrosis factor (ligand) superfamily, member 10	coding-synon

9.0	rs882709	0.005965	SETX	senataxin	coding-nonsynon

10.0	rs4646421	0.007847	CYP1A1	Cytochrome P450, family 1, subfamily A, polypeptide 1	intron

11.0	rs1799969	0.008221	ICAM1	Intercellular adhesion molecule 1 (CD54), human rhinovirus receptor	coding-nonsynon

12.0	rs3822430	0.009157	SRD5A1	Steroid-5-alpha-reductase, alpha polypeptide 1 (3-oxo-5 alpha-steroid delta 4-dehydrogenase alpha 1)	coding-synon

13.0	rs7903344	0.009471	CHUK	Conserved helix-loop-helix ubiquitous kinase	coding-nonsynon

14.0	rs13926	0.011531	TRAP1	TNF receptor-associated protein 1	coding-nonsynon

15.0	rs3172469	0.012006	BCL6	B-cell CCL/lymphoma 6 (zinc finger protein 51)	intron

16.0	rs215101	0.012028	ABCC1	ATP-binding cassette, sub-family C (CFTR/MRP), member 1	intron, TagSNP:ABCC1

17.0	rs2227564	0.012246	PLAU	Plasminogen activator, urokinase	coding-nonsynon

18.0	rs3096057	0.012484	CSF1	Colony stimulating factor 1 (macrophage)	Promoter

19.0	rs6474491	0.013935	STAR	Steriodogenic acute regulator	Promoter

20.0	rs2066471	0.015231	MTHRF	5, 10-methlyenetetrahydrofolate reductase (NADPH)	intron


 	AA-MF	GMP-MF	p

Energy

 kcal/d	2,266 ± 263	2,566 ± 204	0.26

kcal from MF/d	544 ± 100	763 ± 118	0.049

kcal from NF/d	1,722 ± 229	1,802 ± 127	0.77

Protein

 g protein/d	79 ± 4	81 ± 6	0.70

g protein from MF/d	57 ± 5	55 ± 7	0.72

g protein from NF/d	21 ± 2	26 ± 4	0.32

Calcium : phosphorus ratio3

 Ca : P ratio/d	1.06 ± 0.14	1.19 ± 0.17	0.13

Ca : P ratio from MF/d	0.96 ± 0.14	1.22 ± 0.04	0.03

Ca : P ratio from NF/d	0.90 ± 0.27	1.38 ± 0.66	0.28

Vitamin D2

 IU vitamin D/d	630 ± 230	680 ± 167	0.75

IU vitamin D from MF/d	623 ± 182	593 ± 131	0.82

IU vitamin D from NF/d	54 ± 30	60 ± 26	0.81

Calcium2

 mg calcium/d	1,745 ± 274	1,898 ± 270	0.69

mg calcium from MF/d	1,282 ± 240	1,408 ± 264	0.58

mg calcium from NF/d3	416 ± 78	484 ± 76	0.39

Magnesium

 mg magnesium/d	568 ± 62	684 ± 113	0.27

mg magnesium from MF/d	362 ± 68	400 ± 68	0.43

mg magnesium from NF/d	206 ± 30	284 ± 77	0.37

Phosphorus

 mg phosphorus/d	1,836 ± 228	1,749 ± 161	0.62

mg phosphorus from MF/d	1,183 ± 229	1,131 ± 195	0.80

mg phosphorus from NF/d	653 ± 58	618 ± 69	0.70

Potassium

 mg potassium/d	3,249 ± 403	3,699 ± 383	0.40

mg potassium from MF/d	1,100 ± 307	1,388 ± 175	0.39

mg potassium from NF/d	2,149 ± 324	2,311 ± 302	0.70

Sodium

 mg sodium/d2	2,559 ± 298	3,487 ± 334	0.006

mg sodium from MF/d	499 ± 123	1,251 ± 176	0.017

mg sodium from NF/d2	2,060 ± 271	2,236 ± 270	0.48


Category	Male (n = 129)	Female (n = 108)	P-value

Mean (sd)	Mean (sd)

Confidence to undertake endodontic treatment	11.34 (2.65)	09.87 (2.83)	0.001*

Training/Support for undertaking more endodontic treatment in NHS primary dental care	11.33 (2.48)	11.12 (2.41)	0.51

Dissatisfaction with endodontic service access	11.72 (2.25)	12.05 (2.19)	0.051

Acceptability/Support for DwSI services	15.09 (2.05)	15.58 (1.68)	0.047

Interest in training as an endodontic DwSI	3.48 (1.36)	3.51 (1.41)	0.82


			MF (ε = 10)	PHIA (ε = 14)

PDB code	Name	length	low energy	high score	low energy	high scoring

1ad5	Hck kinase	58	22.6	38.4	23.6	36.1

1csk	Csk	56	37.3	48.5	27.0	38.5

1fmk	c-Src	60	32.4	43.5	33.8	45.9

	average		34.9	46.6	32.8	44.4


Citation	Mosquito Species	Diet Components	Success Rate

1955. Lea et al. [57]	Aedes aegypti, Ae. quadrimaculatus	Skimmed milk with 10% honey.	The authors state that skimmed milk can be a substitute for blood to produce eggs. An. quadrimaculatus was also fed proteose-peptone, liver concentrate, and casein hydrolysate.

1955. Dimond et al. [58]	Aedes aegypti	Mixture of 18 amino acids in 10% honey water.	A low egg number of 5.2 eggs/female is reported

1990. Kogan [56]	Aedes aegypti	Porcine albumin (102 mg/mL), γ-globulin (15 mg/mL), hemoglobin (8 mg/mL), ATP (1 mM), NaCl (5–10 mM), and NaHCO3 (120 mM) in water.	101 ± 6.8 eggs/female

1996. Cosgrove and Wood [59]	Aedes aegypti	Porcine albumin (100 mg/mL), γ-globulin (15 mg/mL), hemoglobin (8 mg/mL), isoleucine (2.5 mg/mL), ATP (1 mM), NaCl (5–10 mM), and NaHCO3 (120 mM) in water.	55.32 ± 4.1 eggs/female. 61.9% hatch rate

1996. Cosgrove and Wood [59]	Aedes aegypti	Bovine serum albumin (100 mg/mL), γ-globulin (30 mg/mL), hemoglobin (8 mg/mL), and ATP (1 mM) in Ringer‘s solution.	64.56 ± 5.1 eggs/female. 54.1% hatch rate. A colony of Ae. aegypti was raised on this diet for more than 25 generations

1996. Griffith and Turner [60]	Culex quinquefasciatus	Soy milk formula (33 mg/mL), γ-globulin (11.5 mg/mL), ovalbumin (76.5 mg/mL), ATP (1 mM), NaCl (150 mM), and NaHCO3 (100 mM) in water. 	116 eggs/female. Colonies were maintained for 6 and 15 generations

2014. Pitts [61]	Aedes albopictus	Bovine serum albumin (200 mg/mL) and ATP (1 mM) in phosphate buffered saline. 	92.2 ± 4.4 eggs/female. 71.8% ± 6.1% hatch rate. Colonies were maintained for 6 generations

2015. Gonzales et al. [32]	Aedes aegypti	Bovine serum albumin (200 mg/mL), ATP (1 mM), and iron (III) chloride (0.5 mg/mL) in Aedes physiological saline. 	66 ± 10.8 eggs/female. 33.06% ± 12.34% hatch rate

Citation	Mosquito Species

1955. Lea et al. [57]	Aedes aegypti, Ae. quadrimaculatus

1955. Dimond et al. [58]	Aedes aegypti

1990. Kogan [56]	Aedes aegypti

1996. Cosgrove and Wood [59]	Aedes aegypti

1996. Cosgrove and Wood [59]	Aedes aegypti

1996. Griffith and Turner [60]	Culex quinquefasciatus

2014. Pitts [61]	Aedes albopictus

2015. Gonzales et al. [32]	Aedes aegypti

Diet Components	Success Rate

Skimmed milk with 10% honey.	The authors state that skimmed milk can be a substitute for blood to produce eggs. An. quadrimaculatus was also fed proteose-peptone, liver concentrate, and casein hydrolysate.

Mixture of 18 amino acids in 10% honey water.	A low egg number of 5.2 eggs/female is reported

Porcine albumin (102 mg/mL), γ-globulin (15 mg/mL), hemoglobin (8 mg/mL), ATP (1 mM), NaCl (5–10 mM), and NaHCO3 (120 mM) in water.	101 ± 6.8 eggs/female

Porcine albumin (100 mg/mL), γ-globulin (15 mg/mL), hemoglobin (8 mg/mL), isoleucine (2.5 mg/mL), ATP (1 mM), NaCl (5–10 mM), and NaHCO3 (120 mM) in water.	55.32 ± 4.1 eggs/female. 61.9% hatch rate

Bovine serum albumin (100 mg/mL), γ-globulin (30 mg/mL), hemoglobin (8 mg/mL), and ATP (1 mM) in Ringer‘s solution.	64.56 ± 5.1 eggs/female. 54.1% hatch rate. A colony of Ae. aegypti was raised on this diet for more than 25 generations

Soy milk formula (33 mg/mL), γ-globulin (11.5 mg/mL), ovalbumin (76.5 mg/mL), ATP (1 mM), NaCl (150 mM), and NaHCO3 (100 mM) in water.	116 eggs/female. Colonies were maintained for 6 and 15 generations

Bovine serum albumin (200 mg/mL) and ATP (1 mM) in phosphate buffered saline.	92.2 ± 4.4 eggs/female. 71.8% ± 6.1% hatch rate. Colonies were maintained for 6 generations

Bovine serum albumin (200 mg/mL), ATP (1 mM), and iron (III) chloride (0.5 mg/mL) in Aedes physiological saline.	66 ± 10.8 eggs/female. 33.06% ± 12.34% hatch rate


Indicator a,b	Overall Diet	Quintiles of the Contribution of Ultra-Processed Foods to Total Energy Intake	Standardized Regression Coefficient

Mean	SE	Q1	Q2	Q3	Q4	Q5	Crude	Adjusted c

Energy intake (kcal/d)	1764.71	8.55	1732.00	1766.35	1784.89	1776.38	1763.96	0.02	0.03

Percentage of energy intake from:


Type of services	Quantitative indicators (Survey of female workers)	Qualitative indicators

Hotline	• Frequency of services• Ranking frequent topic of call• Number of calls over time• % of women ever heard about the services• % of women ever used services• Ranking about quality/importance of services	• In-depth information about issues when implementing services from service provider (hotline expert)• In-depth information about relevance, quality and usefulness of services from female workers

Map of health care services providers	• Number of health services provided surveyed and presented in map• % of women ever received map• % of women ever used map to find health care providers• Ranking about quality/importance of services	• In-depth information about relevance, quality and usefulness of services from female workers

SMS	• Frequency of services• Number of SMS developed• Number of SMS sent over time• Major topic of SMS sent• % of women ever heard about the services• % of women ever used services• Ranking about quality/importance of services	• In-depth information about relevance, quality and usefulness of services from female workers


Author (Year)	Number of patients with seminoma	Residual disease	Necrosis/scar

Chong et al (1986) [8]	5	1 (20%)	4 (80%)

Greist et al (1984) [7]a	1	NA	NA


	All tumors	TC	AC	LCNEC

Clinical status at last f/u

Alive without recurrence	35	30	5	0

Alive with recurrence	2	0	1	1

Alive, unknown	7	6	0	1

Died with disease	8	0	1	7

Died of other causes	2	2	0	0

Died, unknown cause	1	1	0	0

Median disease free survival (months)†	NR	NR	35.5	10.1

Hazard ratio		<0.01	0.10	1.00

Confidence interval (95%)		-	0.01-0.57	-

P-value	-	<0.0001	0.0063	-

Mean DFS follow-up (months)	20.2	21.9	21.9	12.0

Median survival (months)	NR	NR	NR	19.7

Hazard ratio		0.06	0.08	1.00

Confidence interval (95%)		0.01-0.24	0.00-0.54	-

P-value	-	<0.0001	0.0070	-

Mean OS follow-up (months)	29.6	31.4	34.3	18.3


Drug	Route	IC50(μM)	Max serum level (μM)	Elimination half life	Efficacy	Mode of action

Aclarubicin	IV	0.94	0.34	13.3 hrs	-122.30	Topoisomerase I and II inhibitor

Actinomycin D	IV	0.38	0.02-0.08	36 hrs	-112.51	Inhibitors of DNA synthesis

Bortezomib	IV	0.34	0.16-0.31	9-15 hrs	-77.11	Proteasome inhibitor;

Carboquone	PO/IV	0.75	0.62-0.74 (200-240 ng/mL)	0.5 hrs	-119.79	Alkylating agents

Ciclopirox	Topical	0.64	N/A - topical only	2.2 hrs in rabbits	-61.11	Chelation of polyvalent metal cations

Deslanoside	 	0.34	0.16	51 hrs	-110.35	Na+/K + ATPase inhibition;

Digitoxin	IV	0.08	0.05-0.2	4-9 days	-109.13	Na+/K + ATPase inhibition;

Digoxin	PO/IV	0.19	0.003	36-48 hrs	-111.40	Na+/K + ATPase inhibition;

Ecteinascidin	IV	0.01	Up to 0.05	50-180 hrs	-116.82	Disruption of DNA strand

Homoharringtonine	SQ	0.21	0.176	9.3 hrs	-125.33	Protein synthesis inhibitor

Lanatoside A	IV/PO	0.19	N/A	N/A	-114.10	Na+/K + ATPase inhibition;

Lanatoside C	IV/PO	0.3	N/A	N/A	-117.82	Na+/K + ATPase inhibition;

Methotrexate	PO/IV	0.02	10-100	8-15 hrs	-74.91	DHFR inhibitor

Metildigoxin	PO/IV	0.24	N/A	N/A	-110.90	Na+/K + ATPase inhibition;

Niclosamide	PO/IV	0.27	N/A	N/A	-94.29	Uncouple oxidative phosphorylation

Ouabain	IV	0.08	0.128	18 hrs	-110.64	Na+/K + ATPase inhibition;

Plicamycin	IV	0.94	0.6 μM	10.5 hrs	-117.62	RNA synthesis inhibitor;

Proscillaridin A	IV/PO	0.01	0.019 (IV); 0.0019 (PO)	23-33 hrs	-110.55	Na+/K + ATPase inhibition;

Pyrimethamine	PO/IV	0.75	8.04	140-190 hrs	-81.43	DHFR inhibitor

Rotenone	N/A	0.75	N/A	N/A	-69.22	Electron transport chain in mitochondria interference

Trimetrexate glucuronate	IV	0.01	N/A	11-16 hrs	-80.39	DHFR inhibitor


Results	Data Frequency (Hz)

10

Training instances	729,097

Test instances	6,561,871

Overall accuracy (%)	99.963

Time (s)	304.86


Dataset	Description	Updated	Genes	Reference

hg18rpa	Protein-coding genes on autosomal chromosomes (based on human genome hg18 and RefSeq genes)	2011	18,166	[35]

HI	Recombination hotspots intersected genes	2010	1,156	-

MI	Recombination middle spots intersected genes	2010	1,481	-

CI	Recombination cold spots intersected genes	2010	1,594	-

HK	Housekeeping genes	2011	1,974	[36]

SPD	Genes encoding secreted proteins	2010	1,667	[37]

TiGER	Tissue-specific genes	2008	4,710	[38]

DGD	Duplicated genes	2012	4,393	[16]

AGE	Genes classified by different evolutionary age	2011	16,418	[17]

OMIM	Mendelian disorder associated genes in human	2012	2,624	[39]

MD	Mendelian Disease Genes (at least one mutation in the particular gene is causative of the disease)	2011	1,629	[21]

CGC	Genes with mutations have been causally implicated in cancer	2011	424	[23]

TICdb	Reciprocal translocation associated genes in human tumours	2008	240	[40]

dbCRID	Chromosomal rearrangement associated genes in human diseases	2010	401	[22]

InteCR	Integrated chromosomal rearrangement associated genes in human diseases (Combined of dbCRID, TICdb and CGC genes)	2012	614	-


	Inoculated andContacts vs.Controls	Inoculated vs.Contacts	Carriers vs.Non-Carriers

SAA	<0.0001***	0.61	0.49

IFN	<0.0001***	0.43	0.27

Haptoglobin	<0.0001***	0.04*	0.015*


Gene name	Sequence (5’–3’)

β-actin	Sense: TCTTGGGTATGGAGTCCTGAntisense: TAGAAGCATTTGCGGTGG

FGA	Sense: GCAGAACAGCATCCAGGAGCAGGAntisense: TCCACCTGGTAATCAAAACTTCTAGCAC

CA2	Sense: CACTGGCACGAGCACTTCAntisense: ACTTCACGCCATCCACAGT

KRT7	Sense: CTGGACGGGTTGTTAAATAntisense: TCCGCTTCGTAGAGAGAT

GRTP1	Sense: GGCTGCTCCAACGCCCACTTAntisense: CGCAACGCCTTCTGCTCTTT

MnSOD	Sense: CTGACCTGCCCTACGACTAntisense: TGGTATGATTGATATGACCC

LOC429524	Sense: GGAGGAAATGCGGCGCTTAGAntisense: GGCTGGACGAGACGCTGTTGA

ATP5A1	Sense: CAGTTTGGGTCTGATTTGGAntisense: AGCTTAGCTTCCGTCTGG

FKBP4	Sense: TACCTCCCAATGCTACGCAntisense: CCTTCGCCTTTCTTACGG

GOT1	Sense: GCACAGACCCTACTCCAGACAntisense: AAGCCCTCGGAGACAAAG

LMNA	Sense: GGGGAACTGGCAGGTGAAGCAntisense: CCTCGTCGTCGTCGTTGATG

PTGDS	Sense: CCGAGGTCTTTTGTTTGAntisense: AGGAGGGGGACTTTGATG

HSPβ1	Sense: CAAACACGAGGAGAAACAAntisense: CGTTTATTCAAGGCACTG

Apo A-I	Sense: TCCGCTTCGTAGAGAGATGTGAntisense: TCAGCGTGTCCAGGTTGTC


Socio-demographic factors

Female

Low income

Primary school only

Smoking (current)

Body Mass Index ≥27

Functioning

Severe cognitive impairment(MMSE < 19)

Depressive symptoms (GDS-15 > 4)

Disability in daily living †

Co-morbidities

Diabetes mellitus

Stroke

Cancer

Benign Prostatic Hyperplasia(IPSS score ≥8)

UTI between the ages of 85 and 86 years

Unintentional loss of faeces

Self-reported urine incontinence

Medical diagnosis incontinence

PRAFAB score ≥11

PRAFAB: Pad use

Creatinine clearance < 30 mL/minute

CRP > 5 mg/L


Variable	Unadjusted	Adjusted

OR	95%CI	p	OR	95%CI	p

Level 1a – Demographic characteristics

Education level			< 0.001			0.024

High school and university (C/I)	1.00			1.00

Basic education (C)	1.71	1.09–2.67		1.27	0.73–2.19

Basic education (I)/Illiterate	3.10	1.99–4.82		2.02	1.17–3.47

Access to telephone			0.001			0.006

Yes	1.00			1.00

No	2.95	1.58–5.52		2.45	1.28–4.70

Level 2b – Behavioral characteristics

Religion			0.044			0.012

No religion	1.00			1.00

Catholic	1.16	0.77–1.74		1.70	1.07–2.68

Evangelical	0.68	0.45–1.03		0.86	0.53–1.39

Number of pregnancies including current one		0.002			0.008

1	1.00			1.00

2–3	1.64	1.11–2.43		1.77	1.12–2.79

≥ 4	2.23	1.39–3.58		2.27	1.30–3.95

Number of sex partners in the last 12 months	< 0.001			0.004

1	1.00			1.00

2	1.93	1.18–3.17		1.66	0.93–2.97

≥ 3	4.60	2.42–8.75		3.15	1.51–6.53

Age at which started using drugs (years)		< 0.001			0.003

Does not use	1.00			1.00

≥ 18	1.83	0.73–4.60		0.50	0.16–1.53

≤ 17	5.66	3.03–10.56		3.04	1.45– 6.40

Current partner uses drugs			<0.001			0.026

No	1.00			1.00

Yes	2.26	1.47–3.47		1.78	1.07–2.98

Level 3c – Clinical, obstetric, and health care history in prenatal care and maternity hospital

Number of appointments in the prenatal care	< 0.001			< 0.001

≥ 7	1.00			1.00

6–4	1.31	0.86–2.00		1.48	0.88–2.49

3–1	3.60	2.17–5.98		3.53	1.86–6.69

No prenatal care	4.47	2.53–7.90		3.20	1.36–7.54

History of previous STI			< 0.001			< 0.001

				1.0


Setting	Number of hours	Number of days	Time period

999	170	41	Nov 2008 – Jul 2010

SPA	172	33	Oct 2009 – July 2010

OOH	149	27	Sept 2009 – Aug 2010

Total	491	101	Nov 2008 – Aug 2010


Substance	Mechanism	Cancer Type	Reference

β-asarone	p53/Bcl-2/Bclin-1 and p53/AMPK/mTOR pathways	Glioma cell line (U251)	[161]

Walsuronoid B	ROS-formation and activation of p53/PI3K/Akt/mTOR signaling pathway	Liver cancer (HepG2 and Bel-7402)	[166]

Sulforaphane	Reduction of phosphorylation of Akt and mTOR	Malignant mesothelioma (H-28)	[167]

Physapubescin B	(ROS)-mediated suppression of mTORC1	Colon cancer (HCT116) and cervical cancer (HeLa)	[168]

Fluvastatin	p53/AMPK/mTOR pathway	Lung adenocarcinoma (A549 and SPC-A-1)	[169]

Trichostatin A and Valproic Acid	ROS formation	Pancreatic cancer (Panc1 and PaCa44)	[170]

Cobalt chloride	p53/Bcl-2/Beclin-1 pathway	Malignant glioma (U87-MG)	[162]

Oridonin	AMPK deactivation-mediated GLUT1 downregulation in p53-mutated cells	p53-mutated colorectal cancer cells (HCT-15, COLO205, HCT116, RKO, SW480, and SW620)	[171]

Astemizole-Histamine	ROS formation and p53 phosphorylation, which increased p53-p62 interactions to enhance Beclin-1-independent autophagy	breast cancer (MCF-7)	[172]

Polygonatum odoratum lectin	Up-regulation of miR-15a-3p, which mediated ROS-p53 pathway	human lung adenocarcinoma (A549)	[173]

Trichosanthin	ROS-formation and activation of p53/PI3K/Akt/mTOR signaling pathway,	gastric cancer (MKN-45)	[174]

Honokiol	ROS-formation and activation of p53/PI3K/Akt/mTOR signaling pathway	Glioma (U87 MG)	[175]

Substance	Mechanism	Cancer Type	Reference

Walsuronoid B	ROS-formation and activation of p53/PI3K/Akt/mTOR signaling pathway	Liver cancer (HepG2 and Bel-7402)	[166]

Sulforaphane	Reduction of phosphorylation of Akt and mTOR	Malignant mesothelioma (H-28)	[167]

Physapubescin B	(ROS)-mediated suppression of mTORC1	Colon cancer (HCT116) and cervical cancer (HeLa)	[168]

Fluvastatin	p53/AMPK/mTOR pathway	Lung adenocarcinoma (A549 and SPC-A-1)	[169]

Trichostatin A and Valproic Acid	ROS formation	Pancreatic cancer (Panc1 and PaCa44)	[170]

Cobalt chloride	p53/Bcl-2/Beclin-1 pathway	Malignant glioma (U87-MG)	[162]

Oridonin	AMPK deactivation-mediated GLUT1 downregulation in p53-mutated cells	p53-mutated colorectal cancer cells (HCT-15, COLO205, HCT116, RKO, SW480, and SW620)	[171]

Astemizole-Histamine	ROS formation and p53 phosphorylation, which increased p53-p62 interactions to enhance Beclin-1-independent autophagy	breast cancer (MCF-7)	[172]

Polygonatum odoratum lectin	Up-regulation of miR-15a-3p, which mediated ROS-p53 pathway	human lung adenocarcinoma (A549)	[173]

Trichosanthin	ROS-formation and activation of p53/PI3K/Akt/mTOR signaling pathway,	gastric cancer (MKN-45)	[174]

Honokiol	ROS-formation and activation of p53/PI3K/Akt/mTOR signaling pathway	Glioma (U87 MG)	[175]


	Practice (n=number of participating GPs at commencement)

Organisational Characteristics	Eastvale (n = 5)	Gibson (n = 1)	Frank (n = 4)	Southville (n = 7)	Coopers (n = 7)	West Sanders (n = 9)

Funding Structure

 Privately owned primary care sites	Y	Y	Y	Y

 Corporatised primary care site						Y

 Publicly funded community health centre					Y

Location

 Urban	Y	Y			Y	Y

 Outer Urban				Y

 Regional			Y

Personnel employed in the practice (in total)

 GP(s)	6	2	4	8	8	14

 Practice nurse(s)	2	3	2	4	2	3

 Registrar(s)	1	0	0	0	0	1

 Psychologist(s)	1	1	0	2	1	1

 Practice manager(s)	1	0	1	1	1	1

 Receptionist(s)	6	2	3	10	5	7

 Other	2	0	2	7	10	0

	Practice (n=number of participating GPs at commencement)

Organisational Characteristics	Eastvale (n = 5)	Gibson (n = 1)	Frank (n = 4)

Funding Structure

Privately owned primary care sites	Y	Y	Y

Corporatised primary care site

Publicly funded community health centre

Location

Urban	Y	Y

Outer Urban

Regional			Y

Personnel employed in the practice (in total)

GP(s)	6	2	4

Practice nurse(s)	2	3	2

Registrar(s)	1	0	0

Psychologist(s)	1	1	0

Practice manager(s)	1	0	1

Receptionist(s)	6	2	3

Other	2	0	2

Practice (n=number of participating GPs at commencement)

Southville (n = 7)	Coopers (n = 7)	West Sanders (n = 9)

Y

		Y

	Y

	Y	Y

Y

8	8	14

4	2	3

0	0	1

2	1	1

1	1	1

10	5	7

7	10	0


Variables	Adjusted odds ratio	95% confidence interval	p-value

Therapeutic Self-Care	0.74	0.56, 0.96	0.03

Over age 75	1.01	0.77, 1.34	0.93

Female	0.77	0.63, 0.96	0.02

Polypharmacy	1.11	0.87, 1.44	0.40

Polypharmacy*Therapeutic Self-Care	1.48	1.10, 2.02	0.01

CHESS Scores	1.42	1.14, 1.76	<0.01

Congestive Heart Failure	1.66	1.20, 2.30	<0.01

Alzheimer’s Disease	1.31	1.01, 1.70	0.02

Model Fit Assessment	Chi-Square	DF	p-value

Likelihood Ratio	68.28	10	<0.01

Model Fit Assessment	Association of Predicted Probabilities and Observed Responses

C-index	0.62


			Fold change

SAGE tag	RefSeq accession	Gene ID	Caudal/rostral (SAGE)	Caudal/rostral (RT-qPCR)

gttgttcttccagtcgg	NM_016916	bladder cancer associated protein homolog (human), Blcap	2.68	1.43

gtcatagctgttctgtg	BC025816	EST sequence BC025816	Cs	1.31 (NS)

aagcttgacatttggaa	NM_026187	ankyrin repeat and zinc finger domain containing 1, Ankzf1	Rs	1.17† (NS)

gatacttggaatgacta	NM_007393	actin, beta, cytoplasmic, Actb	-2.63	-1.32

ttggtgaaggaaaaaac	NM_021278	thymosin, beta 4, X chromosome, Tmsb4x	-2.33	-2.13 (NS)


	OHIP-14 Subscales Characteristics	DMFT category	Statistics Spearman Ranks (rs) correlationa

		Acceptable DMFT <3 N = 341% = 48.7Mean subscale (S.D)	Average DMFT 4–10N = 220% = 31.4Mean subscale (S.D)	Poor DMFT > 10N = 139% = 19.9Mean subscale (S.D)

1.	Functional Limitation	2.1056 (1.95252)	2.8545 (1.93660)	3.1871 (2.05563)	0.234

2.	Physical pain	0.5073 (.96289)	0.7545 (0.99484)	0.8489 (1.10934)	0.160

3.	Psychological discomfort	3.3842 (2.39034)	4.1136 (1.95633)	4.6403 (1.89968)	0.221


Target gene	Primer name	Nucleotide sequence (5'–3')	Product size (bp)	PCR profile (°C/s)	Reference

Denaturation	Annealing	Extension	Cycles

17 kDa	Rr17k. 1p	TTTACAAAATTCTAAAAACCAT	539	95/30	57/60	72/120	35	[23]

Rr17k. 539n	TCAATTCACAACTTGCCATT

Rr17k. 90p	GCTCTTGCAACTTCTATGTT	450	95/30	57/60	72/120	35

Rr17k. 539n	TCAATTCACAACTTGCCATT

ompA	Rr190k. 71p	TGGCGAATATTTCTCCAAAA	650	95/30	42/35	60/120	35	[23]

Rr190k. 720n	TGCATTTGTATTACCTATTGT

Rr190k. 71p	TGGCGAATATTTCTCCAAAA	532	95/30	48/60	65/120	35

Rr190k. 602n	AGTGCAGCATTCGCTCCCCCT

Target gene	Primer name	Nucleotide sequence (5'–3')	Product size (bp)	PCR profile (°C/s)	Reference

Denaturation	Annealing	Extension	Cycles

17 kDa	Rr17k. 90p	GCTCTTGCAACTTCTATGTT	450	95/30	57/60	72/120	35	[23]

Rr17k. 539n	TCAATTCACAACTTGCCATT

ompA	Rr190k. 71p	TGGCGAATATTTCTCCAAAA	650	95/30	42/35	60/120	35	[23]

Rr190k. 720n	TGCATTTGTATTACCTATTGT

Rr190k. 71p	TGGCGAATATTTCTCCAAAA	532	95/30	48/60	65/120	35

Rr190k. 602n	AGTGCAGCATTCGCTCCCCCT


 Type	Number of cases

Detected	Misreported	Under-reported	Total

Probe	226	4	7	233

DoS	131	14	23	155

R2L	77	12	12	89

U2R	29	12	8	36


Feature of presenting complaint	Study participants (n = 30)

Trauma (%)

 Yes	16 (53.3)

 No	14 (46.7)

Weight-bearing (%)

 Yes	17 (56.7)

 No	13 (43.3)

Side affected (%)

 Right	11 (36.7)

 Left	18 (60.0)

 Both	1 (3.3)

Region affected (%)

 Hip	5 (16.7)

 Thigh	8 (26.7)

 Knee	6 (20.0)

 Lower leg	8 (26.7)

 Ankle	3 (10.0)

Diagnosis (%)

 Soft tissue injury	13 (43.3)

 Irritable hip	9 (30.0)

 Toddler’s fracture	3 (10.0)

 Other	4 (13.3)

 Unknown diagnosis	1 (3.3)


Evaluation	Any Difference(Mack Skillings Test)

	Raw P Value

CD4+	0.0203

CD8+	0.0207

CD56+	-

CD16+/CD56+	-

CD25+	0.3192

CD27+	0.0709

NK+ granzyme B+	0.2623

CD8+ granzyme B+	0.0948

NK activity	0.0207

ADCC w/IL2	0.2818

ADCC	0.5095

S100	-

IL6	0.0366

sIL2R	<0.0001

TNF	0.1948

IL10	0.0115

Neopterin	<0.0001


Month(s)	NT-proBNP (fmol/ml)	IL-6 (pg/ml)	Adiponectin (ng/ml)


	p-value 	Pearson correlations

Infant age (month) 	0.002 	-0.270

Height at birth (cm) 	0.010 	0.237

Weight at birth (kg) 	0.940 	-0.007

Head circumference at birth (cm) 	0.251 	0.157

	p-value	Pearson correlations

Head circumference at birth (cm)	0.251	0.157


Annotation category	Number of annotations

Natural antisense lncRNA	64

Pseudogene	75

Transposable element gene	10

Transposase	46

miRNA primary transcript	4

Hypothetical protein	5

Protein	8

Other	8

Annotation category	Number of annotations

Transposable element gene	10

Transposase	46

miRNA primary transcript	4

Hypothetical protein	5

Protein	8

Other	8


Sharing platform	Current users, n = 200n (%)

Do not share data	130	(65.0%)

Tracker support software	70	(35.0%)

Strava	9	(4.5%)

Facebook	7	(3.5%)

Instagram	2	(1.0%)

In person	2	(1.0%)

Twitter	1	(0.5%)

Other	3	(1.5%)

Reasons for sharing on social media

Do not share data on social media	154	(77.0%)

To compete with friends	33	(16.5%)

To share progress	18	(9.0%)

To motivate others	17	(8.5%)

To get encouragement from others	13	(6.5%)

Other	4	(2.0%)


Clinicopathological features	n	BICD1 expression, n (%)

	523	Low, n=262 (50.1)

Age

<65	347	183 (52.7)

≥65	176	79 (44.9)

Gender

Female	205	111 (54.1)

Male	318	151 (47.5)

MGMT expression

Low	262	124 (47.3)

High	261	138 (52.9)

Overall survival indicator

0 (censor)	89	43 (48.3)

1 (death)	434	219 (50.5)

Molecular Subclassification

Neural	87	70 (80.5)

Proneural	138	91 (65.9)

Mesenchymal	156	71 (45.5)

Classical	142	30 (21.1)


Variable	Opium addicted N=50	Non addicted  N=50	P value

Age Mean±SD	36.00±6.54	35.38±6.7	0.64

BMI Mean±sD	21.96±3.46	24.27±3.85	0.002

Cigarrette smoking No. (%)	37 (77.1)	34 (61)	0.31

Vertebral BMD frequency (%)

Normal	22 (44)	37 (74)	0.002

Osteopenia	28 (56)	13 (26)

Lumbar measurement Mean±SD	0.92±0.12	1.01±0.12	0.001

Variable	Opium addicted N=50	Non addicted  N=50	P value

BMI Mean±sD	21.96±3.46	24.27±3.85	0.002

Cigarrette smoking No. (%)	37 (77.1)	34 (61)	0.31

Vertebral BMD frequency (%)

Normal	22 (44)	37 (74)	0.002

Osteopenia	28 (56)	13 (26)

Lumbar measurement Mean±SD	0.92±0.12	1.01±0.12	0.001


National policies and guidelines

Recording and Reporting tools

Collaboration and communication between TB and HIV control programmes

Leadership and commitment

Target setting at all levels of the health care system

Human resources: recruitment, training, support, task shifting

Financing

National Partnerships for results

Providing TB and HIV services under one roof

National policies and guidelines

Leadership and commitment

Target setting at all levels of the health care system

Human resources: recruitment, training, support, task shifting

Financing

National Partnerships for results

Providing TB and HIV services under one roof


Gene	Primers

ABCG2	Primer1: 5′-TGGCTTAGACTCAAGCACAGC-3′

Primer2: 5′- TGGTCCCTGCTTAGACATCC-3′

MRP1	Primer1: 5′-TGTGGGAAAACACATCTTTGA-3′

Primer2: 5′-CTGTGCGTGACCAAGATCC-3′

MRP2	Primer1: 5′-AGTGAATGACATCTTCACGTTTG-3′

Primer2: 5′-CTTGCAAAGGAGATCAGCAA-3′

MDR1	Primer1: 5′-ACAGAAAGCGAAGCAGTGGT-3′

Primer2: 5′-ATGGTGGTCCGACCT TTTC-3′

CD44	Primer1: 5′-GCCTTGGCTTTGATTCTTGC-3′

Primer2: 5′-TCCACTTGGCTTTCTGTCCTC-3′

HES1	Primer1: 5′-GAAAGATAGCTCGCGGCAT-3′

Primer2: 5′'-GAAGCGGGTCACCTCGTT-3′

Krt15	Primer1: 5′-GCTGCTTGACATAAAGACACG-3′

Primer2: 5′'-ATTGCTGCTGCTACCACCA-3′

Oct-4	Primer1: 5′-GGAAGGTATTCAGCCAAACGACCA-3′

Primer2: 5′'-CTCACTCGGTTCTCGATACTGGTT-3′

Sox2	Primer1: 5′-TTCGATCCCAACTTTCCAT-3′

Primer2: 5′'-ACATGGATTCTCGGCAGAC-3′

GAPDH	Primer1: 5′-GCCGGTGCTGAATATGTC-3′

Primer2: 5′-CTTCTGGGTGGCAGTGAT-3′

Gene	Primers

Oct-4	Primer1: 5′-GGAAGGTATTCAGCCAAACGACCA-3′

Primer2: 5′'-CTCACTCGGTTCTCGATACTGGTT-3′

Sox2	Primer1: 5′-TTCGATCCCAACTTTCCAT-3′

Primer2: 5′'-ACATGGATTCTCGGCAGAC-3′

GAPDH	Primer1: 5′-GCCGGTGCTGAATATGTC-3′

Primer2: 5′-CTTCTGGGTGGCAGTGAT-3′


Study	Running distance	Running period	OA induced	Method	Effect

Sekiya et al. [5] 2009	30 km	6 weeks	No		Harmful

Siebelt et al. [24] 2011	31.8 km	6 weeks	No		Harmful

Beckett et al. [17] 2012	30 km / 55 km	3 / 6 weeks	No		Harmful

Pap et al. [20] 1998	30 km	12 weeks	Yes	Intracranial self stimulation	Harmful

Siebelt et al. [21] 2014	15 km	6 weeks	Yes	Papain injection	Harmful

Saito et al. 2015	15 km	3 weeks	Yes	MIA 0.1 mg injection	Harmful

Galois et al. [22] 2004	15 km	4 weeks	Yes	ACLT	Beneficial

Cifuentes et al. [23] 2010	15 km	8 weeks	Yes	MIA 1.2 mg injection	Beneficial


	Baseline Value	Source(s)

Input variables

 Chest pain is caused by ACS	0.1	[19-22]

 GP Sensitivity with ECG	0.818	Unpublished data from [8,11-16]

 GP Sensitivity without ECG	0.667	Unpublished data from [8]

 GP Specificity with ECG	0.5	[12-16]

 GP Specificity without ECG	0.3	[17]

 Correctly referred STEMI patients receiving thrombolysis (%)	58.5	[6]

 Relative risk reduction of thrombolytics	0.750	[23,24]

Costs (2007 US$)

 GP visit	1.76	[37]

 ECG	1.93	[39,40,42-44]

 Emergency department visit	3.48	[37]

 Streptokinase	117.00	[38,45]

 Admission	157.55	[37]

 Blood transfusion	107.67	[37]

 Stroke	211.37	[37]

 Annual secondary prevention	16.56	[37,38]


#	Author	Year	Compound	Strain	Dose	Rote	Test	(Model)

1	Nagase et al. 	2002 	TAN-67 	SD 	1-10 mg/kg 	s.c. 	FSS

2	Broom et al. 	2002 	SNC80 	SD 	10-100 mg/kg 	s.c. 	FSS

3	Broom et al. 	2002 	(+) BW373U86 	SD 	1-10 mg/kg 	s.c. 	FSS

4	Saitoh et al. 	2004 	SNC80 	ICR 	0.3-3 mg/kg 	s.c. 	FSS/CSM

5	Torregrossa et al. 	2005 	(+) BW373U86 	SD 	10 mg/kg X 1, 8, 21 days 	s.c. 	FSS

6	Naidu et al. 	2007 	(-) NIH11082 	C57BL6 	8-32 mg/kg 	i.p. 	TST

7	Saitoh et al. 	2008 	SNC80 	Wistar 	1-10 mg/kg X 7 days 	s.c. 	HE 	OB rat model

8	Vergra et al. 	2008 	UFP-512 	Swiss 	0.001-0.1 nmol/0.01-1 mg/kg 	i.c.v./i.p. 	FSS

9			UFP-512 	SD 	0.1-1 mg/kg 	i.p. 	FSS

10	Le Bourdonnec et al. 	2008 	ADL5859 	- 	0.3-3 mg/kg 	p.o. 	FSS

11	Saitoh et al. 	2011 	KNT-127 	ICR 	0.1-1 mg/kg 	s.c. 	FSS

12	Hudzik et al. 	2011 	AZD2327 	SD 	1-10 mg/kg X 4 days 	p.o. 	LH


 	Predictability of Spherical Equivalent*

 	undercorrection <1.0	1.0 to 0.51	±0.5	0.51 to 1.0	overcorrection >1.0	Total

 	WTR

Number	1	9	34	6	0	50

%	2	18	68	12	0	100

 	Oblique

Number	3	8	38	9	0	58

%	5	14	66	16	0	100

 	ATR

Number	1	6	30	7	1	45

%	2	13	67	16	2	100


Y-Intercept (#/cm3)	Weekday	Weekend

Day	Night	Day	Night

Ultrafine 	50 (5)	101 (8)	43 (11)	143 (7)

Fine 	48 (2)	62 (2)	46 (5)	90 (3)

Y-Intercept (#/cm3)	Weekday

Day	Night

Ultrafine	50 (5)	101 (8)

Fine	48 (2)	62 (2)


QUICKI		tertile 1	tertile 2	tertile 3

	Model	# events	HR (95%CI)	# events	HR (95%CI)	# events	HR (95%CI)


	Haddadi et al.	Huang et al.	Lu &Zoubir	Ours

E(lq)	Lawley	Lawley	Lawley	Lawley

Var(lq)	Multivariate Statistics	Random Matrix	Random Matrix	Lawley

E(Aq)	Lawley	Lawley	Lawley	Lawley

Var(Aq)	- *	-	Random Matrix	Random Matrix


Disability	No or Other Resistance (n = 220)	INH Resistant (n = 86)	RIF Resistant or MDR (n = 16)	Cumulative Odds Ratioa(95% CI)	P Value

		31 	2 	IN


	N	M ± SD

Outcome: Teaching qualitya

 Didactics	499	7.9 ± 1.3

 Learning climate	500	8.4 ± 1.1

 Motivation and enthusiasm	500	8.1 ± 1.3

 Behavior towards patients	488	8.1 ± 1.2

Motivational categoriesb	55 for all

 Intrinsic TM		2.7 ± 0.9

 Identified TM		3.2 ± 0.7

 Introjected TM		0.7 ± 0.8

 External TM		1.5 ± 1.0

 T Amotivation		0.9 ± 0.9

Teaching self-efficacyb	55	2.5 ± 0.5

Situational variablesb	94 for all

 Enough time to prepare lesson		2.1 ± 1.2

 Stress before lesson		2.2 ± 1.1

 Perceived students’ motivation		3.1 ± 0.7

 Perceived students’ competences		2.9 ± 0.8

 Perceived students’ respect		3.6 ± 0.6

Outcome: Teaching qualitya

Didactics

Learning climate

Motivation and enthusiasm

Behavior towards patients

Motivational categoriesb

Intrinsic TM

Identified TM

Introjected TM

External TM

T Amotivation

Teaching self-efficacyb

Situational variablesb

Enough time to prepare lesson

Stress before lesson

Perceived students’ motivation

Perceived students’ competences

Perceived students’ respect


Variant	Minor/major allele	Minor allele frequency

Genotyped and imputed

rs2206593	T/C	0.074


Medical	Nursing

Enhanced scopes of practice

• Physicians are allowed to private practice with specific fees during off hours	• Nurses also are allowed to work in the private sector before and after office hours

Producing new types of health workers

• The programmes for production of other paramedics such as medical assistants, laboratory assistants, pharmacists, and physiotherapy assistants are already in place	• Currently, there are a number of nursing and related programmes, such as BSc nursing, postbasic nursing, diploma in nursing, family welfare assistant, community skilled birth assistants, and community health-care providers

Compulsory service in rural area

• Provision of minimum 2 years of services at Union Health Sub-Centre	• The Nursing Personnel Recruitment Rules were developed in 1985, without any provision of compulsory rural services

• Preference to fill vacancies for remote and hard-to-reach areas/health facilities	• Recently, efforts are underway to introduce provision of compulsory services in rural health facilities

• Provision of non-practicing allowance is given to encourage physicians to purely focus on public services

Subsidized education for return of service

• Provision of scholarships, bursaries, and other training and education subsidies are available, but not particularly focused on rural retention	• Provision of scholarships, bursaries, and other training and education subsidies are available, but not particularly focused on rural retention

dical	g

Enhanced scopes of practice

• Physicians are allowed to private practice with specific fees during off hours	• Nurses also are allowed to work in the private sector before and after office hours

Producing new types of health workers

• The programmes for production of other paramedics such as medical assistants, laboratory assistants, pharmacists, and physiotherapy assistants are already in place	• Currently, there are a number of nursing and related programmes, such as BSc nursing, postbasic nursing, diploma in nursing, family welfare assistant, community skilled birth assistants, and community health-care providers

Compulsory service in rural area

• Provision of minimum 2 years of services at Union Health Sub-Centre	• The Nursing Personnel Recruitment Rules were developed in 1985, without any provision of compulsory rural services

• Preference to fill vacancies for remote and hard-to-reach areas/health facilities	• Recently, efforts are underway to introduce provision of compulsory services in rural health facilities

• Provision of non-practicing allowance is given to encourage physicians to purely focus on public services

Subsidized education for return of service

• Provision of scholarships, bursaries, and other training and education subsidies are available, but not particularly focused on rural retention	• Provision of scholarships, bursaries, and other training and education subsidies are available, but not particularly focused on rural retention


Objection	Primer	Sequences

Murine variable regions of the heavy chain (VH)	VHF	5'-GCTGCCCAACCAGCCATGGCCGAGGTGCAGCTGGTGGAATCGGG-3'

VHR	5'-CGATGGGCCCTTGGTGGAGGCTGCAGAGACAGTGACCAGAGT-3'

Murine variable regions of the light chain (VL)	VkF	5'-GGGCCCAGGCGGCCGAGCTCGATATTTTGCTCACTCAG-3'

VkR	5'-GAAGACAGATGGTGCAGCCACAGTTCGTTTCATTTCCAGTTTGGTCCC-3'

Human constant regions of the heavy chain domain 1 (CH1)	CH1-F	5'-GCCTCCACCAAGGGCCCATCGGTC-3'

dpseq	5'-GATATCAGAAGCGTAGTCCGGAACGTC-3'

Human constant regions of the light chain domain (CL)	HKC-F	5'-CGAACTGTGGCTGCACCATCTGTC-3'

Lead B	5'-AAGCTTGGCCATGGCTGGTTGGGCAGC-3'

Chimeric heavy chain (Fd)	Lead H	5'-CATATGGCTGCCCAACCAGCCATGGCC-3'

dpseq	Ditto

Chimeric light chain	RSF-F	5'-GGATCCGGAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC-3'

Lead B	Ditto

Human constant regions of the heavy chain domain 1 (CH1)	dpseq	5'-GATATCAGAAGCGTAGTCCGGAACGTC-3'

Human constant regions of the light chain domain (CL)	HKC-F	5'-CGAACTGTGGCTGCACCATCTGTC-3'

Lead B	5'-AAGCTTGGCCATGGCTGGTTGGGCAGC-3'

Chimeric heavy chain (Fd)	Lead H	5'-CATATGGCTGCCCAACCAGCCATGGCC-3'

dpseq	Ditto

Chimeric light chain	RSF-F	5'-GGATCCGGAGGAGGAGGAGGAGGAGGCGGGGCCCAGGCGGCCGAGCTC-3'

Lead B	Ditto


		Number of participants (% within category)

Country of graduation and current workplace	Rwanda	13 (76%)

Democratic Republic of the Congo	4 (24%)

Completed whole years since graduation	1 year	6 (35%)

2–3 years	6 (35%)

≥ 4 years	5 (29%)

Gender	Male	15 (88%)

Female	2 (12%)

Desired future specialty	General surgery	12 (71%)

Neurosurgery	2 (12%)

Orthopaedics	1 (6%)

Urology	2 (12%)

		Number of participants (% within category)

Desired future specialty	Urology	2 (12%)


Characteristics	N	Total (%)	Boys (%)	Girls (%)	χ2	p-value

Sexually active

Yes	113	27.2	33.8	21.3	8.29	0.004

No	303	72.8	66.2	78.7

Early sex debut *

Before 15 years	55	48.7	60.6	31.9	9.05	0.003

After 15 years	58	51.3	39.4	68.1

Multiple partner *


Duration of diabetes (years)	7.29 ± 7.9	_

HbA1c (%)	8.2 ± 1.75	_